

1 COOLEY LLP
MICHAEL ATTANASIO (151529)
2 (mattanasio@cooley.com)
BARRETT J. ANDERSON (318539)
3 (banderson@cooley.com)
CRAIG E. TENBROECK (287848)
4 (ctenbroeck@cooley.com)
SOPHIA M. RIOS (305801)
5 (srios@cooley.com)
JAYME B. STATEN (317034)
6 (jstaten@cooley.com)
4401 Eastgate Mall
7 San Diego, CA 92121-1909
Telephone: (858) 550-6000
8 Facsimile: (858) 550-6420

9 *Attorneys for Plaintiff and Counter-Defendant*
ChromaDex, Inc.

10 *Counsel continued on following page*

11
12
13 **UNITED STATES DISTRICT COURT**
14 **CENTRAL DISTRICT OF CALIFORNIA**
15 **(WESTERN DIVISION)**
16

17 ChromaDex, Inc.,
18 Plaintiff,
19 v.
20 Elysium Health, Inc., and Mark Morris
21 Defendants.

22 Elysium Health, Inc.,
23 Counterclaimant,
24 v.
25 ChromaDex, Inc.,
26 Counter-Defendant.
27

Case No. 8:16-cv-2277-CJC (DFMx)

JOINT EXHIBIT LIST

Judge: Hon. Cormac J. Carney
Courtroom: 7C

Pretrial Conference: Sept. 18, 2019
Trial: October 15, 2019

1 COVINGTON & BURLING LLP
MITCHELL A. KAMIN (202788)
2 (mkamin@cov.com)
1999 Avenue of the Stars, Suite 3500
3 Los Angeles, CA 90067-4643
Telephone: (424) 332-4800
4 Facsimile: (424) 332-4749

5 COVINGTON & BURLING LLP
PHILIP A. IRWIN (*admitted Pro Hac Vice*)
6 (pirwin@cov.com)
620 Eighth Avenue
7 New York, NY 10018-1405
Telephone: (212) 841-1000
8

9 *Attorneys for Plaintiff and Counter-Defendant*
ChromaDex, Inc.
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28

1 Pursuant to the Court's August 1, 2019 Order (Dkt. 220) and Local Rule 16-6.1,
2 Plaintiff ChromaDex, Inc., Defendant and Counterclaimant Elysium Health, Inc., and
3 Defendant Mark Morris, hereby submit the following Joint Exhibit List. Pending the
4 Court's decisions on the parties' Motions for Summary Judgment and continued trial
5 preparation, the parties anticipate revising and narrowing the Joint Exhibit List and
6 exhibit numbering before trial.

7
8 Dated: September 11, 2019 COOLEY LLP
9 MICHAEL A. ATTANASIO (151529)
10 BARRETT J. ANDERSON (318539)
11 CRAIG E. TENBROECK (287848)
12 SOPHIA M. RIOS (305801)
13 JAYME B. STATEN (317034)

14 /s/ Michael A. Attanasio
15 Michael A. Attanasio (151529)

16 *Attorneys for Plaintiff and Counter-Defendant*
17 *ChromaDex, Inc.*

18 *The filer, Michael A. Attanasio, attests that the other signatory listed, on whose behalf*
19 *the filing is submitted, concurs in the filing's content and has authorized the filing.*

20 Dated: September 11, 2019 BAKER & HOSTETLER LLP
21 MICHAEL R. MATTHIAS (057728)
22 ELIZABETH M. TRECKLER (282432)
23 JOSEPH N. SACCA (*admitted pro hac vice*)
24 ESTERINA GIULIANI (*admitted pro hac vice*)
25 BENJAMIN D. PERGAMENT
26 (*admitted pro hac vice*)
27 KRISTIN L. KERANEN
28 (*admitted pro hac vice*)

29 /s/ Joseph N. Sacca
30 Joseph N. Sacca (*admitted pro hac vice*)

31 *Attorneys for Defendant and Counterclaimant*
32 *Elysium Health, Inc. and*
33 *Defendant Mark Morris*

JOINT EXHIBIT LIST

Trial Exhibit List - Dated 9/11/2019

Exhibit No.	Date	Description	Date Identified	Date Admitted
1		PDF titled "How Basis is Made"		
2		Excel titled "Inventory Forecast"		
3		PowerPoint titled "Elysium NAD"		
4		PowerPoint titled "Founders Fund"		
5		Word Document titled "NRCI Analytical Method"		
6		Word Document titled "NRCI Process"		
7		Word Document titled "NRCI Specifications"		
8		Excel titled "NRCI Specifications"		
9		PDF titled "Mark Morris - 2015"		
10		Native Excel File		
11		Excel titled "2016, 2017 & 2018 Elysium Health Financials"		
12		Report titled "Method Transfer for Determination of Residual Acetamide in Nictinamide Riboside Chloride by GC"		
13		Excel titled "Inventory Summary 2019."		
14	9/27/2010	PDF titled "AIBMR Life Sciences Agreement 8.24.2010"		
15	4/25/2012	PDF titled "Chromadex Invoice GRAS 10Apr2012"		
16	6/4/2013	Email from M. Morris to M. Morris		
17	7/10/2013	PDF titled "Thorne Research Supply Agreement 7.9.13"		
18	11/9/2013	Email with attachments from F. Jaksch to T. Varvaro		
19	12/13/2013	Email with attachments from F. Jaksch to E. Marcotulli, D. Alminana and R. Prag		
20	12/16/2013	Email from D. Alminana to F. Jaksch, L. Kelly, E. Marcotulli, R. Prag and L. Guarente		
21	12/27/2013	Email from D. Alminana to E. Marcotulli and F. Jaksch		
22	1/10/2014	Email with attachments from D. Alminana to F. Jaksch and E. Marcotulli		
23	1/20/2014	Email with attachments from D. Alminana to F. Jaksch and E. Marcotulli		
24	6/12/2014	Email with attachments from C. Villalobos to D. Alminana and F. Jaksch		
25	6/27/2014	Email with attachments from C. Villalobos to D. Alminana, E. Marcotulli, F. Jaksch and M. Morris		
26	6/27/2014	Email with attachments from D. Alminana to M. Rosa and E. Marcotulli		
27	7/11/2014	Email with attachments from M. Morris to P. Fedorov		

Trial Exhibit List - Dated 9/11/2019

Exhibit No.	Date	Description	Date Identified	Date Admitted
28	7/19/2014	Email with attachments from S. Torbati to C. Villalobos and M. Morris		
29	7/19/2014	Email with attachments from D. Alminana to H. Van Blarcom, E. Marcotulli, F. Jaksch and T. Varvaro		
30	8/25/2014	PDF titled "ChromaDex - pTeroPure"		
31	8/25/2014	PDF titled "ChromaDex - Niagen - Full"		
32	9/12/2014	Email from M. Morris to L. Guarente		
33	10/27/2014	Email with attachments from H. Van Blarcom to A. Waite, M. Morris and C. Villalobos		
34	11/14/2014	Email with attachments from M. Morris to M. Clemens, J. Golder, Z. Mendez and T. Rhonemus		
35	12/12/2014	Email with attachments from B. Teicher to H. Van Blarcom, T. Rhonemus, E. Bullard, C. Villalobos and J. Baltas		
36	2/4/2015	PDF titled "Nexgen supply agreement"		
37	2/18/2015	Email from J. Crespo-Barreto to C. Kruger and D. Conze		
38	3/25/2015	Email with attachments from C. Villalobos to M. Morris		
39	3/26/2015	Email from C. Villalobos to M. Morris and A. Shargh		
40	3/27/2015	Excel titled "Copy of 2015 Budget Final for Presentation"		
41	4/10/2015	PDF titled "CDXA-ARS-23650-00 Internal Acetamide by GC"		
42	4/17/2015	Email from M. Morris to E. Marcotulli, R. Dellinger, D. Alminana		
43	4/17/2015	Email with attachments from D. Alminana to T. Hall, K. Black and E. Marcotulli		
44	4/21/2015	Email with attachments from D. Papinchak to M. Morris and S. Krasnomowitz		
45	4/22/2015	Email with attachments from E. Marcotulli to G. Wang		
46	6/30/2015	Email with attachments from E. Marcotulli to F. Vigil		
47	7/12/2015	Email with attachments from E. Marcotulli to A. Eskin, A. Karnal and D. Alminana		
48	7/12/2015	Email with attachments from E. Marcotulli to N. Jammet and D. Alminana		
49	7/13/2015	Email with attachments from E. Marcotulli to N. Brown and D. Alminana		
50	7/13/2015	Email with attachments from E. Marcotulli to G. Elad		
51	7/13/2015	Email with attachments from E. Marcotulli to V. Vasisht		
52	7/15/2015	Email with attachments from L. Guarente to E. Marcotulli and G. Wang		
53	7/18/2015	Email with attachments from M. Morris to D. Alminana and E. Marcotulli		
54	7/18/2015	Email with attachments from M. Morris to D. Alminana and E. Marcotulli		

Trial Exhibit List - Dated 9/11/2019

Exhibit No.	Date	Description	Date Identified	Date Admitted
55	8/3/2015	Email with attachments from E. Marcotulli to A. Mehta and D. Alminana		
56	8/4/2015	Email with attachments from E. Marcotulli to vishal@obviousventures.com		
57	8/26/2015	Email with attachments from R. Dellinger to E. Marcotulli, D. Alminana and M. Morris		
58	8/26/2015	Email from R. Dellinger to M. Morris, D. Alminana and E. Marcotulli		
59	8/27/2015	Email with attachments from S. Zhang to D. Alminana and E. Marcotulli		
60	8/28/2015	Email with attachments from E. Swick to R. Fried, T. Varvaro, F. Jaksch, T. Klinghoffer and H. Van Blarcom		
61	8/28/2015	Email with attachments from T. Rhonemus to T. Varvaro		
62	8/28/2015	Email with attachments from E. Marcotulli to B. Zakaria		
63	8/31/2015	Email with attachments from T. Vaughan to david@financialdestinyblog.com, T. Rhonemus, H. Van Blarcom and T. Vaughan		
64	8/31/2015	Email from E. Marcotulli to D. Alminana		
65	9/9/2015	Email with attachments from H. Van Blarcom to crichter@lifeextension.com		
66	9/10/2015	PDF titled "HD Notice Letter 090915"		
67	9/11/2015	Email with attachments from E. Marcotulli to sarnold@polarispartners.com and D. Alminana		
68	9/11/2015	Email with attachments from E. Marcotulli to G. Ki and M. Lu		
69	9/11/2015	Email with attachments from E. Marcotulli to A. Mehta		
70	9/16/2015	Email with attachments from E. Marcotulli to A. Mehta		
71	9/27/2015	Email with attachments from Dan Alminana to F. Jaksch, J. Lee, T. Varvaro, E. Marcotulli and M. Morris		
72	9/28/2015	Email with attachments from E. Marcotulli to N. Green, D. Alminana and N. Green		
73	9/28/2015	Email with attachments from E. Marcotulli to sean@seanrad.com and D. Alminana		
74	9/28/2015	Email with attachments from E. Marcotulli to G. Li, D. Alminana, L. Guarente and M. Lu		
75	9/29/2015	Email with attachments from M. Morris to andrew@kgksynergize.com, D. Alminana and E. Marcotulli		
76	9/29/2015	Email with attachments from E. Marcotulli to B. O'Malley, D. Alminana and L. Guarente		
77	9/29/2015	Email with attachments from E. Marcotulli to N. Green, D. Alminana and N. Green		

Trial Exhibit List - Dated 9/11/2019

Exhibit No.	Date	Description	Date Identified	Date Admitted
78	9/29/2015	Email with attachments from E. Marcotulli to G. Li, D. Alminana, L. Guarente and M. Lu		
79	9/29/2015	Email with attachments from E. Marcotulli to sean@seanrad.com and D. Alminana		
80	9/30/2015	Email with attachments from E. Marcotulli to O'Malley, D. Alminana and L. Guarente		
81	10/2/2015	Email with attachments from Dan Alminana to tyler.a.jayroe@jpmorgan.com		
82	10/4/2015	Email with attachments from E. Marcotulli to R. Bradford and D. Alminana		
83	10/4/2015	Email with attachments from E. Marcotulli to J. Durant and D. Alminana		
84	10/9/2015	Email from M. Morris to D. Alminana and E. Marcotulli		
85	10/13/2015	Email with attachments from E. Marcotulli to N. Lichtenstein and D. Alminana		
86	10/13/2015	Email with attachments from E. Marcotulli to R. Madison and D. Alminana		
87	10/13/2015	Email with attachments from E. Marcotulli to A. Fine and D. Alminana		
88	10/13/2015	Email with attachments from E. Marcotulli to N. Lichtenstein and D. Alminana		
89	10/13/2015	Email with attachments from E. Marcotulli to R. Madison and D. Alminana		
90	10/26/2015	PDF titled "AlternaScript Niagen TM Agreement"		
91	10/28/2015	Email with attachments from E. Marcotulli to J. Sures and D. Alminana		
92	10/28/2015	Email with attachments from E. Marcotulli to A. Fine, J. Fine, D. Alminana, L. Guarente, M. Shlomo, M.D.		
93	11/4/2015	Email from D. Alminana to M. Morris and E. Marcotulli		
94	11/25/2015	Email with attachments from D. Alminana to G. Casale, S. Rostami and E. Marcotulli		
95	12/1/2015	Email with attachments from E. Marcotulli to E. Morgan, D. Alminana and E. Morgan		
96	12/9/2015	Email from C. Villalobos to J. Mai		
97	12/15/2015	Email with attachments from Dan Alminana to tmradiology1@yahoo.com and E. Marcotulli		
98	12/15/2015	Email with attachments from Dan Alminana to J. Schwartz and E. Marcotulli		
99	12/26/2015	Email with attachments from Dan Alminana to B. Jordan and E. Marcotulli		
100	12/28/2015	Email from T. Rhonemus to D. Alminana, F. Jaksch and E. Marcotulli		
101	1/5/2016	Email with attachments from T. Rhonemus to D. Alminana, F. Jaksch, E. Marcotulli, H. Van Blarcom, M. Morris and T. Varvaro		
102	1/5/2016	Email with attachments from T. Rhonemus to D. Alminana, F. Jaksch, E. Marcotulli, H. Van Blarcom, M. Morris and T. Varvaro		

Trial Exhibit List - Dated 9/11/2019

Exhibit No.	Date	Description	Date Identified	Date Admitted
103	1/5/2016	Email with attachments from M. Morris to D. Alminana		
104	1/8/2016	PDF titled "Fully Executed - Supply Agreement (BPI and CDX)"		
105	1/12/2016	Email with attachments from C. Villalobos to M. Morris		
106	1/23/2016	Email from T. Rhonemus to D. Alminana, F. Jaksch, E. Marcotulli, H. Van Blarcom, M. Morris and T. Varvaro		
107	1/26/2016	Email with attachments from C. Villalobos to F. Jaksch		
108	2/5/2016	Email from M. Morris to E. Marcotulli and D. Alminana		
109	2/5/2016	Email with attachments from C. Villalobos to D. Alminana, E. Marcotulli and M. Morris		
110	2/8/2016	Email with attachments from L. Kelly to T. Rhonemus		
111	2/9/2016	Email with attachments from Dan Alminana to D. McEnroe and E. Marcotulli		
112	2/11/2016	Email with attachments from Dan Alminana to F. Jaksch, T. Rhonemus, E. Marcotulli and L. Guarente		
113	2/11/2016	Email with attachments from E. Marcotulli to B. Bradley		
114	2/17/2016	Email with attachments from Dan Alminana to C. Castro		
115	2/20/2016	Email with attachments from Dan Alminana to Grace, E. Marcotulli, L. Chen and dan@ikang.com		
116	2/24/2016	Email with attachments from T. Varvaro to S. Zietz, F. Jaksch and T. Rhonemus		
117	3/3/2016	Email with attachments from E. Marcotulli to R. Nelsen		
118	3/3/2016	Email with attachments from E. Marcotulli to C. Bellestar		
119	3/15/2016	Email with attachments from M. Morris to D. Alminana and E. Marcotulli		
120	3/18/2016	Email with attachments from Dan Alminana to R. Granstein and E. Marcotulli		
121	3/21/2016	PDF titled "Barology Niagen Supply Agreement 03.21.16"		
122	3/24/2016	Email with attachments from E. Marcotulli to N. Sirni and D. Alminana		
123	3/24/2016	Email with attachments from E. Marcotulli to J. Klunzinger, B. Johnson, D. Alminana and L. Guarente		
124	3/25/2016	Email with attachments from C. Villalobos to T. Rhonemus, F. Jaksch and M. Morris		
125	4/5/2016	Email from D. Alminana to S. Zhang		
126	4/5/2016	Email with attachments from M. Morris to D. Alminana and E. Marcotulli		
127	4/5/2016	Email from E. Marcotulli to M. Morris and D. Alminana		
128	4/7/2016	Email from E. Marcotulli to D. Alminana and M. Morris		

Trial Exhibit List - Dated 9/11/2019

Exhibit No.	Date	Description	Date Identified	Date Admitted
129	4/8/2016	Email from M. Morris to D. Alminana and E. Marcotulli		
130	4/12/2016	Email from S. Zhang to D. Alminana		
131	4/12/2016	Email from D. Alminana to M. Morris an E. Marcotulli		
132	4/13/2016	Email from L. Bournissaint to D. Alminana and E. Marcotulli		
133	4/14/2016	Email from C. Villalobos to D. Papinchak and J. Roufs		
134	4/14/2016	Email from M. Morris to L. Bournissaint		
135	4/15/2016	PDF titled "\"Leonardi Institute Supply Agreement - Niagen 04.15.16"		
136	4/15/2016	Email from M. Morris to L. Guarente, D. Alminana, E. Marcotulli		
137	4/15/2016	Email from L. Grimaldi to M. Morris, D. Alminana and E. Marcotulli		
138	4/15/2016	Email from E. Marcotulli to M. Morris and D. Alminana		
139	4/26/2016	Email from M. Morris to D. Alminana and E. Marcotulli		
140	4/26/2016	Email from D. Alminana to M. Morris an E. Marcotulli		
141	4/26/2016	Email from D. Alminana to M. Morris an E. Marcotulli		
142	4/29/2016	Email from M. Morris to D. Alminana and E. Marcotulli		
143	4/29/2016	Email from M. Morris to D. Alminana and E. Marcotulli		
144	4/29/2016	Email from E. Marcotulli to D. Alminana and S. Schell		
145	4/29/2016	Email from D. Alminana to S. Schell and E. Marcotulli		
146	4/29/2016	Email from D. Alminana to mark@gersteinlab.org and E. Marcotulli		
147	4/29/2016	Email from S. Schell to D. Alminana, S. Schell and M. Morris		
148	4/29/2016	Email from D. Alminana to S. Schell and M. Morris		
149	5/2/2016	Email from D. Alminana to mark@gersteinlab.org and M. Morris		
150	5/2/2016	Email from M. Morris to D. Alminana		
151	5/4/2016	Email from E. Marcotulli to D. Alminana and L. Guarente		
152	5/4/2016	Email from S. Schell to E. Marcotulli, L. Guarente and D. Alminana		
153	5/25/2016	Email with attachments from J. Mai to C. Lozano and T. Lindsley		
154	5/29/2016	Email from M. Morris to M. Morris		
155	5/29/2016	Email from M. Morris to M. Morris		
156	5/29/2016	Email from M. Morris to D. Alminana and E. Marcotulli		
157	5/30/2016	Email from M. Morris to M. Morris		
158	5/30/2016	Email from M. Morris to M. Morris		
159	5/30/2016	Email from M. Morris to M. Morris		

Trial Exhibit List - Dated 9/11/2019

Exhibit No.	Date	Description	Date Identified	Date Admitted
160	5/30/2016	Email from M. Morris to M. Morris		
161	5/30/2016	Email with attachments from M. Morris to D. Alminana and E. Marcotulli		
162	5/30/2016	Email from E. Marcotulli to D. Alminana and M. Morris		
163	5/31/2016	Email with attachments from M. Morris to M. Morris		
164	6/2/2016	Email from M. Morris to L. Guarente and D. Alminana		
165	6/7/2016	Email from M. Morris to E. Marcotulli		
166	6/13/2016	Email from E. Marcotulli to D. Alminana and M. Morris		
167	6/14/2016	Email from T. Rhonemus to C. Rinsch and M. Morris		
168	6/15/2016	Email with attachments from Dan Alminana to M. Morris and E. Marcotulli		
169	6/16/2016	Email from M. Morris to M. Morris		
170	6/16/2016	Email from M. Morris to D. Alminana and E. Marcotulli		
171	6/17/2016	Email from E. Marcotulli to D. Alminana and M. Morris		
172	6/19/2016	Email with attachments from M. Morris to M. Morris		
173	6/19/2016	Email with attachments from M. Morris to M. Morris		
174	6/19/2016	Email with attachments from M. Morris to D. Alminana and E. Marcotulli		
175	6/19/2016	Email with attachments from M. Morris to D. Alminana and E. Marcotulli		
176	6/19/2016	Email from E. Marcotulli to D. Alminana and M. Morris		
177	6/20/2016	Email from E. Marcotulli to D. Alminana and M. Morris		
178	6/20/2016	Email from M. Morris to E. Marcotulli and D. Alminana		
179	6/20/2016	Email from E. Marcotulli to M. Morris		
180	6/21/2016	Email from T. Rhonemus to B. Reynolds		
181	6/21/2016	Email with attachments from T. Rhonemus to B. Reynolds		
182	6/22/2016	Email with attachments from M. Morris to D. Alminana and E. Marcotulli		
183	6/23/2016	Email from B. Reynolds to T. Rhonemus		
184	6/23/2016	Email with attachments from C. Kruger to stella.si@acclab.cn, bobbi.hu@acclab.cn, D. Zhan, L. Chen, J. Zhou and C. Kruger		
185	6/23/2016	Email from D. Alminana to E. Marcotulli and M. Morris		
186	6/23/2016	Email from C. Castro to M. Morris and D. Alminana		
187	6/24/2016	Email with attachments from D. Magida to D. Alminana		
188	6/26/2016	Email with attachments from Dan Alminana to Morris and E. Marcotulli		
189	6/27/2016	Email with attachments from M. Morris to M. Morris		

Trial Exhibit List - Dated 9/11/2019

Exhibit No.	Date	Description	Date Identified	Date Admitted
190	6/27/2016	Email with attachments from M. Morris to M. Morris		
191	6/27/2016	Email with attachments from M. Morris to M. Morris		
192	6/27/2016	Email with attachments from M. Morris to M. Morris		
193	6/27/2016	Email with attachments from M. Morris to M. Morris		
194	6/27/2016	Email with attachments from M. Morris to M. Morris		
195	6/27/2016	Email from M. Morris to M. Morris		
196	6/27/2016	Email with attachments from M. Morris to M. Morris		
197	6/27/2016	Email with attachments from D. Magida to D. Alminana and E. Marcotulli		
198	6/27/2016	Email from M. Morris to D. Alminana and G. Wang		
199	6/28/2016	Email with attachments from Dan Alminana to F. Jaksch, T. Rhonemus, T. Varvaro, M. Morris, C. Villalobos and E. Marcotulli		
200	6/28/2016	Email from D. Magida to E. Marcotulli and D. Alminana		
201	6/28/2016	Email from M. Morris to G. Wang and D. Alminana		
202	6/28/2016	Email from M. Morris to E. Marcotulli and D. Alminana		
203	6/30/2016	Email with attachments from Dan Alminana to F. Jaksch, C. Villalobos, D. Alminana, E. Marcotulli, M. Morris, T. Varvaro, T. Rhonemus and W. Black		
204	7/5/2016	Email with attachments from M. Morris to M. Morris		
205	7/5/2016	Email from E. Marcotulli to D. Alminana and M. Morris		
206	7/6/2016	Email with attachments from M. Morris to D. Alminana and E. Marcotulli		
207	7/6/2016	Email from E. Marcotulli to D. Alminana and M. Morris		
208	7/6/2016	Email from M. Morris to E. Marcotulli and D. Alminana		
209	7/6/2016	Email from M. Morris to E. Marcotulli and D. Alminana		
210	7/7/2016	Email from E. Marcotulli to D. Alminana and M. Morris		
211	7/9/2016	Email from E. Marcotulli to D. Alminana and M. Morris		
212	7/10/2016	Email with attachments from E. Marcotulli to D. Fallow and D. Alminana		
213	7/10/2016	Email from D. Alminana and E. Marcotulli		
214	7/11/2016	Email from M. Morris to E. Marcotulli and D. Alminana		
215	7/13/2016	Email with attachments from M. Morris to M. Morris		
216	7/14/2016	Email with attachments from M. Morris to D. Alminana and E. Marcotulli		
217	7/14/2016	Email from E. Marcotulli to M. Morris, D. Alminana and J. Schock		
218	7/14/2016	Email from M. Morris to E. Marcotulli and D. Alminana		

Trial Exhibit List - Dated 9/11/2019

Exhibit No.	Date	Description	Date Identified	Date Admitted
219	7/14/2016	Email from E. Marcotulli to G. Wang, L. Guarente and S. Schell		
220	7/15/2016	Email from M. Morris to ChromaDex		
221	7/15/2016	Email with attachments from J. Robles to M. Morris		
222	7/15/2016	Email from M. Morris to J. Robles		
223	7/15/2016	Email with attachments from J. Robles to D. Doan		
224	7/15/2016	Email to M. Morris from A. Erickson		
225	7/15/2016	Email from D. Alminana to E. Marcotulli and M. Morris		
226	7/15/2016	Email with attachments from M. Morris to D. Alminana and E. Marcotulli		
227	7/15/2016	Email from D. Alminana to E. Marcotulli and M. Morris		
228	7/17/2016	Email from E. Marcotulli to D. Alminana and M. Morris		
229	7/18/2016	Excel titled "NR Ingredient Sales Data for all customer"		
230	7/19/2016	Email with attachments from D. Magida to D. Alminana		
231	7/20/2016	Email from M. Morris to M. Morris		
232	7/22/2016	Email with attachments from D. Alminana to R. Dellinger and E. Marcotulli		
233	7/26/2016	Email with attachments from M. Morris to M. Morris		
234	7/27/2016	Email from R. Dellinger to D. Alminana and E. Marcotulli		
235	7/28/2016	Email from M. Morris to J. Schock		
236	8/1/2016	PDF titled "NRCl Process"		
237	8/1/2016	Email from E. Marcotulli to D. Alminana and M. Morris		
238	8/1/2016	Email with attachments from D. Alminana to M. Morris		
239	8/1/2016	Email with attachments from D. Alminana to M. Morris		
240	8/2/2016	Email with attachments from D. Alminana to E. Marcotulli		
241	8/2/2016	Email from M. Morris to M. Morris		
242	8/3/2016	Email with attachments from E. Marcotulli to D. McEnroe, D. Alminana and J. Curran		
243	8/5/2016	PDF titled "2016-08-5_Response_Letter_0635_Final_transmittal"		
244	8/5/2016	Email from R. Dellinger to D. Alminana and E. Marcotulli		
245	8/6/2016	Email from E. Marcotulli to D. Alminana and R. Dellinger		
246	8/8/2016	Email from E. Marcotulli to D. Alminana and R. Dellinger		
247	8/9/2016	Email from R. Dellinger to M. Morris with attachments		
248	8/10/2016	Email from D. Alminana to T. Varvaro, E. Marcotulli, F. Jaksch and T. Rhonemus		

Trial Exhibit List - Dated 9/11/2019

Exhibit No.	Date	Description	Date Identified	Date Admitted
249	8/10/2016	Email with attachments from C. Villalobos to D. Alminana		
250	8/11/2016	Email with attachments from W. Black to T. Varvaro, T. Rhonemus, F. Jaksch		
251	8/11/2016	Email with attachments from T. Varvaro to T. Rhonemus, W. Black and F. Jaksch		
252	8/11/2016	Email from M. Morris to D. Alminana		
253	8/11/2016	Email with attachments from R. Dellinger to D. Alminana, and E. Marcotulli		
254	8/11/2016	Email from D. Alminana to E. Marcotulli and R. Dellinger		
255	8/11/2016	Email with attachments from D. Alminana to R. Dellinger and E. Marcotulli		
256	8/12/2016	Email with attachments from E. Marcotulli to J. Roberts, D. Alminana and D. Fialkow		
257	8/14/2016	Email from E. Marcotulli to D. Givacchini and J. Roberts		
258	8/15/2016	Email with attachments from J. Mai to C. Holloway		
259	8/19/2016	Email with attachments from J. Roberts to D. Alminana, E. Marcotulli, A. Valkin, C. McCain, D. Giovacchini, D. Fialkow and J. Li		
260	8/20/2016	Email from E. Marcotulli to D. Fialkow, M. Hyman, A. Valkin, D. Alminana and J. Roberts		
261	8/21/2016	Email from E. Marcotulli to C. Castro, D. Alminana, D. Fabricant, M. Morris and V. Davis		
262	8/21/2016	Email with attachments from E. Marcotulli to D. Alminana and J. Manzi		
263	8/24/2016	Email with attachments from D. Alminana to E. Marcotulli and M. Morris		
264	8/26/2016	Email from W. Black to G. Horn and F. Jaksch		
265	8/28/2016	Email with attachments from M. Morris to E. Marcotulli, L. Guarente, R. Dellinger and D. Alminana		
266	8/28/2016	Email with attachments from M. Morris to E. Marcotulli, L. Guarente, R. Dellinger and D. Alminana		
267	8/28/2016	Email from M. Morris to D. Alminana, E. Marcotulli and R. Dellinger		
268	8/28/2016	Email from E. Marcotulli to D. Alminana, M. Morris and R. Dellinger		
269	8/29/2016	Email with attachments from J. Roberts to D. Alminana, E. Marcotulli, A. Valkin, C. McCain, D. Giovacchini, D. Fialkow and J. Li		
270	8/30/2016	Email from D. Alminana to T. Varvaro, E. Marcotulli, W. Black, F. Jaksch and T. Rhonemus		
271	8/30/2016	Email with attachments from R. Dellinger to J. Jones		

Trial Exhibit List - Dated 9/11/2019

Exhibit No.	Date	Description	Date Identified	Date Admitted
272	8/31/2016	Email with attachments from M. Morris to L. Guarente, R. Dellinger, D. Alminana and E. Marcotulli		
273	8/31/2016	Email from M. Morris to E. Marcotulli		
274	9/1/2016	Email with attachments from E. Marcotulli to L. Wong, D. Alminana and K. Ho		
275	9/1/2016	Email with attachments from E. Marcotulli to L. Wong, D. Alminana and K. Ho		
276	9/4/2016	Email from B. Reynolds to D. Alminana, E. Marcotulli and L. Guarente		
277	9/7/2016	Email with attachments from D. Alminana to B. Reynolds		
278	9/8/2016	Email with attachments from E. Marcotulli to D. Fialkow, J. Roberts and D. Alminana		
279	9/9/2016	Email with attachments from D. Alminana to E. Marcotulli, G. Wang, L. Guarente, R. Dellinger and M. Morris		
280	9/9/2016	Email with attachments from D. Alminana to E. Marcotulli to G. Wang, L. Guarente, R. Dellinger and M. Morris		
281	9/9/2016	Email from R. Dellinger to D. Alminana, E. Marcotulli, G. Wang, L. Guarente and M. Morris		
282	9/13/2016	Email with attachments from J. Lee to T. Varvaro		
283	9/14/2016	PDF titled "Excelsior Nutrition"		
284	9/15/2016	Email with attachments from W. Black to P. Jacobson		
285	9/15/2016	Email from B. Reynolds to T. Rhonemus		
286	9/16/2016	Email from W. Black to P. Jacobson, F. Jaksch and T. Rhonemus		
287	9/23/2016	Email with attachments from W. Black to G. MacEachern		
288	9/24/2016	Word document titled "CGMP Letter"		
289	9/26/2016	Email from W. Black to T. Varvaro, F. Jaksch and T. Rhonemus		
290	9/28/2016	Email from T. Rhonemus to B. Reynolds		
291	9/29/2016	Email with attachments from D. Magida to D. Alminana and E. Marcotulli		
292	9/30/2016	Email with attachments from J. Mai to D. Southwick		
293	9/30/2016	Email from T. Rhonemus to A. Beninati and B. Reynolds		
294	9/30/2016	Email from T. Rhonemus to A. Beninati, B. Reynolds and T. Varvaro		
295	9/30/2016	Email from T. Rhonemus to A. Beninati, A. Reynolds, T. Varvaro and H. Van Blarcom		
296	9/30/2016	Email from former contract manufacturer to M. Morris		
297	9/30/2016	Email with attachments from R. Dellinger to J. Curran		

Trial Exhibit List - Dated 9/11/2019

Exhibit No.	Date	Description	Date Identified	Date Admitted
298	10/3/2016	Email with attachments from R. Dellinger to J. Berger		
299	10/7/2016	Email from E. Marcotulli to D. Giovacchini, D. Fialkow, J. Roberts and O. Lew		
300	10/12/2016	Email with attachments from J. Mai to D. Southwick		
301	10/12/2016	Email with attachments from J. Mail to george@vitamonk.com		
302	10/12/2016	Email with attachments from M. Heck to H. Van Blarcom and J. Mai		
303	10/13/2016	Email with attachments from D. Magida to K. Kohan		
304	10/14/2016	Email with attachments from R. Dellinger to A. Lin and J. Berger		
305	10/17/2016	Email with attachments from E. Marcotulli to D. Giovacchini and J. Roberts		
306	10/17/2016	Email with attachments from D. Magida to J. Kamarack		
307	10/18/2016	Email from T. Rhonemus to B. Reynolds		
308	10/21/2016	Email from B. Reynolds to T. Rhonemus and T. Varvaro		
309	10/24/2016	Email with attachments from T. Rhonemus to B. Reynolds, T. Varvaro, H. Van Blarcom, A. Beninati and T. Rhonemus		
310	10/25/2016	PDF titled "ProHealth, Inc Trademark License Agreement 10.24.2016"		
311	10/25/2016	Email with attachments from J. Mai to G. Macon		
312	10/25/2016	Email from B. Reynolds to T. Rhonemus, T. Varvaro, H. Van Blarcom and A. Beninati		
313	10/26/2016	Email with attachments from M. Rueffer to R. Dellinger and S. Roel Santos		
314	10/27/2016	Email with attachments from M. Rueffer to R. Dellinger and S. Roel Santos		
315	11/1/2016	Email with attachments from to D. Alminana, E. Marcotulli and S. Block		
316	11/1/2016	Email from D. Magida to D. Alminana		
317	11/1/2016	Email with attachments from F. Jaksch to D. Alminana, E. Marcotulli and S. Block		
318	11/1/2016	Email from E. Marcotulli to D. Alminana and L. Guarente		
319	11/2/2016	Email from E. Marcotulli to D. Alminana		
320	11/3/2016	Word document titled "Memo - Q3 2016 Going Concern v2"		
321	11/3/2016	Email with attachments from M. Morris to E. Marcotulli		
322	11/7/2016	Word document titled "Trump Securities Invoice_Chromadex"		
323	11/8/2016	Email from D. Magida to J. Moore and M. Morris		
324	11/9/2016	Email with attachments from J. Lee to T. Varvaro		
325	11/11/2016	Email with attachments from M. Morris to D. Alminana, E. Marcotulli, R. Dellinger and S. Roel Santos		

Trial Exhibit List - Dated 9/11/2019

Exhibit No.	Date	Description	Date Identified	Date Admitted
326	11/14/2016	Email with attachments from T. Blaser to T. Varvaro and T. Rhonemus		
327	11/14/2016	Email with attachments from M. Morris to S. De Brabandere		
328	11/18/2016	PDF titled "Alivebynature, Inc. Supply Agreement 11.18.2016"		
329	11/18/2016	Email from E. Marcotulli to M. Morris, D. Alminana and R. Dellinger		
330	11/21/2016	Email from B. Reynolds to T. Rhonemus		
331	11/26/2016	Email with attachments from R. Dellinger to E. Marcotulli		
332	11/27/2016	Email with attachments from M. Morris to K. Kohan and D. Magida		
333	11/28/2016	Email with attachments from E. Marcotulli to A. Lin		
334	11/29/2016	Email with attachments from E. Marcotulli to J. Berger		
335	12/1/2016	Email from B. Reynolds to T. Rhonemus and T. Varvaro		
336	12/5/2016	Email from T. Varvaro to T. Blaser		
337	12/9/2016	PowerPoint titled "Sales Marketing Strat (002)_Reto input"		
338	12/9/2016	Email from E. Marcotulli to C. Castro, D. Alminana and S. Roel Santos		
339	12/9/2016	Email with attachments from C. Castro to J. Berger, A. Sun, A. Lin, J., Daeun, D. Alminana, E. Ivansson, E. Marcotulli, J. Curran, S. Roel Santos and T. Brooks		
340	12/13/2016	PowerPoint titled "Sales Marketing Strat Final"		
341	12/13/2016	Email from M. Morris to AQPR LLC and D. Magida		
342	12/15/2016	PDF titled "5Linx Enterprises Farshad Tafazzoli Notice of Term 12.15.2016"		
343	12/15/2016	Email from former contract manufacturer to M. Morris		
344	12/16/2016	Email from M. Morris to E. Marcotulli, D. Alminana and S. Roel Santos		
345	12/19/2016	Email from M. Morris to M. Morris		
346	12/22/2016	Email with attachments from M. Heck to H. Van Blarcom, J. Mai and R. Rieder		
347	12/22/2016	Email with attachments from J. Lee to T. Varvaro		
348	1/5/2017	Email with attachments from System Administrator to T. Rhonemus and F. Jaksch		
349	1/5/2017	Email with attachments from J. Robles to T. Varvaro		
350	1/6/2017	Email with attachments from E. Marcotulli to D. Alminana, S. Obrien and W. Nolin		
351	1/6/2017	Email with attachments from R. Dellinger to D. Alminana, E. Marcotulli, L. Guarente and M. Morris		
352	1/7/2017	Email with attachments from R. Dellinger to D. Alminana, E. Marcotulli and M. Morris		
353	1/9/2017	PDF titled "Conf. Agreement_MMorris_081407"		

Trial Exhibit List - Dated 9/11/2019

Exhibit No.	Date	Description	Date Identified	Date Admitted
354	1/10/2017	Email with attachments from H. Van Blarcom to J. Mai		
355	1/10/2017	Email from B. Reynolds to T. Rhonemus		
356	1/17/2017	Email from M. Morris to C. Donovan		
357	1/20/2017	Email with attachments from J. Moore to D. Magida		
358	1/27/2017	Email with attachments from J. Mai to R. Jollymore		
359	2/16/2017	Email with attachments from J. Lee to E. Bechold, O. Kobyakova and T. Varvaro		
360	2/20/2017	Email with attachments from J. Lee to T. Varvaro		
361	2/20/2017	Email with attachments from M. Morris to D. Alminana		
362	2/21/2017	Email with attachments from R. Dellinger to J. Yen		
363	2/24/2017	Excel titled "Dan Alminana iPhone7_A1661_Report"		
364	2/24/2017	Excel titled "Dan Alminana iPhoneSE_A1662_Report"		
365	2/25/2017	Excel titled "Eric_Marcotulli iPhone6_A1549_Report"		
366	3/1/2017	Email with attachments from M. Morris to D. Alminana		
367	3/2/2017	PDF titled "Grace Amendment Manufacturing & Supply Agreement 3.1.2017_fully executed"		
368	3/13/2017	Word document titled "Memo - YE 2016 Going Concern (Revised 03032017 Clean)"		
369	3/15/2017	Email with attachments from R. Dellinger to R. Rebry		
370	3/24/2017	Email with attachments from R. Dellinger, D. Donovan, J. Ellis, R. Butt		
371	4/3/2017	Email with attachments from D. Giovacchini, S. Roel Santos, D. Alminana and E. Marcotulli		
372	4/17/2017	Email with attachments from M. Morris to C. Donovan		
373	4/17/2017	Email from M. Morris to former contract manufacturer		
374	4/18/2017	Email from former contract manufacturer to former contract manufacturer		
375	4/19/2017	Email from M. Morris to former contract manufacturer and D. Alminana		
376	4/21/2017	Email with attachments from H. Van Blarcom to B. Teicher		
377	4/21/2017	Email with attachments from H. Van Blarcom to jim@GlobalRadiantHealth.com		
378	4/21/2017	Email from M. Morris to A. Sweet		
379	4/22/2017	Email with attachments from H. Van Blarcom to drdave@go2lehi.com		
380	4/24/2017	Email with attachments from M. Morris to C. Donovan		
381	4/25/2017	Email with attachments from R. Dellinger to R. Rebry and J. Ellis		
382	4/26/2017	PDF titled "MAAC10 Notice of Term Supply Agreement Niagen 4.26.2017"		

Trial Exhibit List - Dated 9/11/2019

Exhibit No.	Date	Description	Date Identified	Date Admitted
383	4/26/2017	PDF titled "SM Empreendimentos Farmaceuticos LTDA Supply Agreement 4.26.2017"		
384	4/26/2017	PDF titled "Evolved Organics Supply Agreement Niagen 4.26.2017"		
385	4/26/2017	Email with attachments from D. Magida to E. Marcotulli, D. Alminana, K. Iles, M. Morris, S. Roel Santos		
386	4/27/2017	Email from M. Morris to former contract manufacturer		
387	4/28/2017	PDF titled "Alivebynature, Inc. Notice of Term Niagen Supply Agreement 4.26.2017 Diff Address"		
388	4/28/2017	Email from former contract manufacturer to M. Morris		
389	5/2/2017	PDF titled "High Performance Nutrition Supply Agreement 5.2.2017"		
390	5/2/2017	PDF titled "Thrive Now Health LLC David Newren Notice of Term Niagen Supply Agreement 5.2.2017"		
391	5/2/2017	Email with attachments from H. Van Blarcom to D. Wren		
392	5/3/2017	Email with attachments from R. Rebry to M. Morris, J. Ellis, R. Dellinger and W. Rowe		
393	5/4/2017	Email with attachments from R. Dellinger to E. Fletes		
394	5/8/2017	Excel titled "Supply/Trademark Agreements - NIAGEN"		
395	5/8/2017	Word document titled "Memo - Q1 2017 Going Concern (05082017)"		
396	5/9/2017	Email with attachments from former contract manufacturer to M. Morris		
397	5/9/2017	Email from D. Alminana to former manufacturer		
398	5/10/2017	Email with attachments from L. Kelly to D. Ward, H. Blarcom and T. Rhonemus		
399	5/10/2017	Email from M. Morris to C. Donovan, D. Alminana, D. Magida and former manufacturer		
400	5/12/2017	Email with attachments to T. Lau		
401	5/18/2017	Word Document titled "Meeting Minutes 2-3-17"		
402	5/19/2017	Email with attachments from H. Blarcom to Jenna		
403	5/22/2017	Email with attachments from M. Morris to current manufacturer		
404	5/25/2017	PDF titled "Barology Niagen Supply Agreement Letter 5.25.2017"		
405	5/25/2017	PDF titled "High Performace Nutrition LLC ltr re TLA 5.25.2017"		
406	5/25/2017	PDF titled "Jarrow Formulas, Inc. Niagen Supply Agreement Letter 5.25.2017"		

Exhibit No.	Date	Description	Date Identified	Date Admitted
407	5/25/2017	PDF titled "Life Extension Quality Supplements & Vitamins Notice of Term Niagen Supply Agreement Letter 5.25.2017"		
408	5/25/2017	PDF titled "Pretiva LLC Niagen Supply Agreement Letter 5.25.2017"		
409	5/25/2017	PDF titled "ProHealth, Inc\ProHealth, Inc. Notice of Term Niagen Supply Agreement Letter 5.25.2017"		
410	5/25/2017	PDF titled "SM Empreendimentos Farmaceuticos LTDA Niagen Supply Agreement Letter 5.25.2017"		
411	5/25/2017	PDF titled "ProHealth, Inc. Notice of Term Niagen Supply Agreement Letter 5.25.2017"		
412	5/26/2017	Email with attachments from M. Heck to J. Mai and E. Vieira		
413	5/29/2017	Email with attachments from R. Dellinger to D. Rosmarin, R. Granstein and L. Guarente		
414	6/1/2017	PDF titled "Thorne Research New Trademark Agreement Letter 5.26.2017"		
415	6/1/2017	PDF titled "Thorne Research New Trademark Agreement Letter 5.26.2017"		
416	6/5/2017	Letter with attachments from H. Blarcom to Nextar7 LLC		
417	6/22/2017	PDF titled "Nectar7 David D'Arcangelo Inventory Purchase Letter 6.22.2017"		
418	7/5/2017	PDF titled "Elysium MSA"		
419	7/6/2017	PDF titled "Pretiva LLC Angelo Pollastrone Notice of Term Niagen Supply Agreement 7.5.2017"		
420	7/6/2017	Email with attachments from former manufacturers to M. Morris, R. Padilla and others		
421	7/7/2017	Email with attachments from M. Morris to M. Morris		
422	7/11/2017	Email from M. Morris to current manufacturer		
423	7/12/2017	Email from C. Donovan to D. Magida, M. Morris and R. Padilla		
424	7/17/2017	Email with attachments from former manufacturer to M. Morris, D. Magida and R. Padilla		
425	8/15/2017	Email with attachments from D. Magida to M. Morris and R. Padilla		
426	8/28/2017	Email from E. Marcotulli to A Ciechanover, P. Modrich, T. Sudhot, D. Almanina, L. Guarente and R. Dellinger		
427	8/28/2017	Email with attachments from R. Dellinger to D. Xu, I Dean and T Abunadi		
428	8/29/2017	Email from E. Marcotulli to R. Dellinger and T. Sudhoff		

Trial Exhibit List - Dated 9/11/2019

Exhibit No.	Date	Description	Date Identified	Date Admitted
429	8/29/2017	Email with attachments from R. Dellinger to O. Chen		
430	8/29/2017	Email with attachments from M. Morris to L. Brown and W. Rowe		
431	8/29/2017	Email with attachments from M. Morris to L. Brown		
432	9/1/2017	Email from K. Kohan to R. Padilla and M. Patel		
433	9/7/2017	Email with attachments from M. Morris to D. Alminana and E. Marcotulli		
434	9/7/2017	Email with attachments from R. Dellinger to M. Morris		
435	9/7/2017	Email from M. Patel to R. Padilla and K. Kohan		
436	9/20/2017	Email from G. Bank to M. Morris		
437	10/3/2017	Email with attachments from D. Ward to T. Rhonemus		
438	10/3/2017	Email with attachments from R. Dellinger to F. Beasley and M Morris		
439	10/25/2017	PDF titled "Thorne Research, Inc. Supply Agreement 07.09.2013"		
440	11/3/2017	Email with attachments from R. Rieder to W. Black and H. Blarcom		
441	11/6/2017	Email from M. Morris to G. Bank, A. Evans and S. Overgaard		
442	11/7/2017	Email from E. Marcotulli to R. Nelsen		
443	11/9/2017	Email with attachments from R. Dellinger to M. Morris, M. Welborn		
444	11/26/2017	Email with attachments from R. Fried to W. Yu		
445	11/29/2017	Email with attachments from R. Dellinger to J. Baur, C. Sims and H. Holmes		
446	12/5/2017	Email from M. Morris to M. Kashyap, M. Seagar, K. Khurana, J. Pinkhasov and D. Peel		
447	12/19/2017	Email with attachments from R. Dellinger to D. Alminana, E. Marcotulli, K. Iles, and T. Wilhelm		
448	1/4/2018	Email with attachments from D. Alminana to B. Barnett, S. Santos, E. Marcotulli and M. Morris		
449	1/4/2018	Email with attachments from D. Magida to A. Hoover		
450	1/9/2018	PDF titled "Product Fact Sheet Niagen 2017 final"		
451	1/10/2018	Email with attachments from R. Dellinger, E. Chini, K. Mendes, M. Martins and M. Morris		
452	1/11/2018	Email with attachments from M. Morris to J. Pinkhasov		
453	1/14/2018	Excel titled "2018 Budget (01092018 Working"		
454	1/18/2018	Email from A. Marinescu to M. Morris and J. Pinkhasov		
455	2/1/2018	Email with attachments from B. Barnett to D. Alminana, M. Morris and R. Dellinger		

Exhibit No.	Date	Description	Date Identified	Date Admitted
456	2/4/2018	Email with attachments from S. Santos, E. Marcotulli, D. Alminana, P. Gurevich		
457	2/4/2018	Email with attachments from E. Marcotulli to M. Brooks and R. Foo		
458	2/22/2018	PDF titled "Rejuvenation Therapeutics Supply Agreement 9.4.15"		
459	2/28/2018	PDF titled "ChromadexCorp_10K_20160317"		
460	2/28/2018	PDF titled "ChromadexCorp_10K_20170316"		
461	2/28/2018	PDF titled "ChromadexCorp_10Q_20160512"		
462	2/28/2018	PDF titled "ChromadexCorp_8K_20150303"		
463	6/27/2018	PDF titled "BVA - Elysium 409a Valuation Report FINAL 6.27.2018"		
464	7/26/2018	PDF titled "ChromaDex - Establishing the Canadian Market Context"		
465	7/26/2018	PDF titled "Healthy Aging&Cognitive Brain Health_Insights_DE2"		
466	9/25/2018	PDF titled "Mark Morris Paystubs 010116 through 123116"		
467	11/13/2018	PDF titled "1808-001 Acetamide in NR-CI Investigation by GC-MS-FID_DRAFT2"		
468	8/1/2016	Email with attachment from Morris to former manufacturer		
469	8/2/2016	Email with attachment from Morris to former manufacture		
470	8/8/2016	Email with attachment from former manufacturer to Morris		
471	8/7/2016	Former manufacturer proposal for the Development and Synthesis of Nicotinamide - D-Riboside Chloride Prepared for Elysium		
472	12/15/2016	Email from D. Alaminana to former manufacturer, M. Morris, E. Marcotulli		
473	12/22/2016	Email with attachment from former manufacturer to M. Morris		
474	1/10/2017	Email from former manufacturer to M. Morris		
475	2/20/2017	Email from former manufacturer to M. Morris		
476	4/7/2017	Email from former manufacturer to Morris		
477	4/7/2017	Email with attachment from former manufacturer to M. Morris		
478	5/23/2017	Email from M. Morris to former manufacturer and D. Alminana		
479	5/24/2017	Email with attachment from former manufacturer to M. Morris, D. Magida and D. Alminana,		
480	7/11/2017	Email from former manufacturer to M. Morris, and Alaminana		
481	7/5/2017	Email with attachment from M. Morris to former manufacturer and D. Alminana		
482	5/11/2017	Email from D. Alminana to former manufacturer, M. Morris and D. Magida		
483	5/2/2017	Document Approval; Assay and Purity Determination of Nicotinamide Riboside Chloride by HPLC - CAD		

Trial Exhibit List - Dated 9/11/2019

Exhibit No.	Date	Description	Date Identified	Date Admitted
484	9/28/2016	Email with attachment from Morris to former manufacturer R. Dellinger		
485	8/29/2016	Former manufacturer external meeting minutes		
486	8/30/2016	Email from M. Morris to former manufacturer		
487	9/26/2016	Former manufacturer project objective and summary		
488	10/24/2016	Former manufacturer project objective and summary		
489	12/19/2016	Former manufacturer external meeting minutes		
490	12/20/2016	Email from former manufacturer to M. Morris		
491	11/7/2016	Former manufacturer analytical summary		
492	2/1/2017	Email from former manufacturer to M. Morris		
493	3/7/2017	Letter from former manufacturer to M. Morris		
494	4/27/2017	Email from M. Morris to former manufacturer		
495	4/28/2017	PDF titled "Document Approval; Method Qualification Protocol - (AM-C_QC-1170) Assay and Purity Determination of Nicotinamide Riboside Chloride by HPLC-CAD"		
496	7/6/2017	Email from M. Morris to former manufacturer		
497	8/8/2017	Email with attachment from former manufacturer to M. Morris, D. Magida, R. Padilla		
498	11/15/2017	Email from M. Morris to former manufacturer and R. Padilla and A. Marinescu		
499	1/17/2018	Letter from former manufacturer to R. Padilla		
500	1/9/2017	Email from former manufacturer		
501	3/12/2018	Email with attachment from former manufacturer to M. Morris		
502	7/14/2017	PDF titled "Document Approval; Determination of Residual Acetamide in Nicotinamide Riboside Chloride by GC"		
503	7/27/2017	PDF titled "Document Approval; Method Qualification Report - (AM-C-QC-1245) Determination of Residual Acetamide in Nicotinamide Riboside-chloride by GC"		
504	8/29/2017	PDF titled "Document Approval; Determination of Residual Acetamide in Nicotinamide Riboside Chloride by GC"		
505	1/4/2018	Email with attachment from D. Magida to A. Hovert		
506	1/4/2018	Excel titled "Inventory Summary - Elysium Health_1.04.18_xlsx Raw Materials"		
507	1/4/2018	Excel titled "Inventory Summary - Elysium Health_1.04.18_xlsx Unit Economic Cost"		
508	1/4/2018	Excel titled "Inventory Summary - Elysium Health_1.04.18_xlsx Basis Lots"		
509	6/17/2016	Email from E. Marcotulli to D. Magid and D. Alminana		
510	6/21/2016	Email with attachment from D. Magida to D. Alminana		

Trial Exhibit List - Dated 9/11/2019

Exhibit No.	Date	Description	Date Identified	Date Admitted
511	6/24/2016	Email with attachment from D. Magida to D. Alminana		
512	6/27/2016	Email with attachment from D. Magida to D. Alminana and E. Marcotulli		
513	6/28/2016	Email with attachment from D. Magida to E. Marcotulli and D. Alminana		
514	5/8/2016	Email with attachment from D. Magida to D. Alminana and E. Marcotulli		
515		Excel titled "Elysium Health Model.xlsx No PR Expanded Forecast"		
516		Excel titled "Elysium Health Model.xlsx Ordering"		
517	9/28/2016	Email from D. Magida to E. Marcotulli and D. Alminana		
518	9/29/2016	Email with attachment from D. Magida to E. Marcotulli and D. Alminaana		
519		Excel titled "EH-Model thru 2017.xlsx Expanded Forecast"		
520	11/1/2016	Email from D. Magida to D. Alminana		
521	10/14/2016	Email from Moris to Magida and Dellinger re Ideal overage for NR/Ptero		
522	12/13/2016	Email from AQPR LLC to E. Morris and D. Magida		
523	5/11/2017	Email from D. Alminana to E. Morris and D. Magida		
524	10/13/2016	Email with attachment from D. Magida to K. Kohan		
525	10/17/2016	Email with attachment from D. Magida to J. Skamarack		
526	11/5/2016	PDF titled "Supply Chain Update Presentation"		
527	11/8/2016	Email with attachment from D. Magida to J. Moore and M. Morri		
528		PDF titled "Nicotinamide Riboside Chloride by HPLC"		
529	6/13/2017	Email from D. Aliminana to D. Magida and M. Morris		
530		Excel titled "Inventory Forecast.xlsx Forecast"		
531	1/22/2019	Excel titled "Ingredient Sales"		
532	1/22/2019	PowerPoint titled "Tru Niagen Customer Survey FINAL Report 9-7-2018 v3 (005)"		
533	1/25/2019	Excel titled "NR Sales Profits Costs (June 2013 to Dec 2018)"		
534	2/1/2019	M. Morris Dropbox folder re NR		
535	2/1/2019	M. Morris Dropbox folder re Pterostilbene		
536	2/15/2019	Excel titled "December 2018 Financial Reporting (02012019)"		
537	2/25/2019	M. Morris Dropbox folder re Cote Documents		
538	2/25/2019	M. Morris Dropbox folder re Mayo - NR		
539	7/23/2010	PDF titled "Retracted SIRT1 Suppresses B-Amyloid Production by Activiating the a-Secetase Gene ADAM10"		

Trial Exhibit List - Dated 9/11/2019

Exhibit No.	Date	Description	Date Identified	Date Admitted
540	5/14/2004	PDF titled: "Discoveries of Nicotinamide Riboside as a Nutrient and Conserved NRK Genes Establish a Preiss-Handler Independent Route to NAD in Fungi and Humans"		
541	5/4/2017	PDF titled "Nicotinamide Riboside Promotes Sir2 Silencing and Extends Lifespan via Nrk and Urh1/Pnp1/Meu1 Pathways to NAD+"		
542	8/22/2016	PDF titled "An MIT Scientist Claims That This Pill Is the Fountain of Youth Leonard Guarente is certain he's succeeded where doctors (and quacks) before him have failed. His pill will either extend lives or tarnish his career"		
543	1/6/2017	PDF titled "Criticas Blast Star-Studded Advisory Board of Anti-Aging Company"		
544	5/26/2016	PDF titled "The Anti-Aging Supplement Gold Mine"		
545	5/27/2016	Email from E. Marcotulli to L. Guarente		
546	10/2/2014	Email from E. Marcotulli to L. Guarente		
547	4/29/2016	Email from Marcotulli to D. Alminana and L. Guarente		
548	4/22/2015	Email from R. Dellinger to L. Guarente		
549	4/22/2015	Email from E. Marcotulli to L. Guarente and D. Alminana		
550	10/28/2015	Email from E. Marcotulli to J. Fine, A. Fine, S. Melmed, D. Alminana and L. Guarente		
551	12/24/2015	Email from Marcotulli to G. Church, L. Guarente and D. Alminana		
552	8/31/2016	Email from Morris to L. Guarente, R. Dellinger, E. Marcotulli and D. Alminana		
553	11/24/2017	PDF titled "Repeat dose of NRPT (nicotinamide riboside and pterostilbene) increases NAD+ levels in human safely and sustainably: a randomized, double-blind, placebo-controlled study"		
554	8/20/2018	PDF titled: "Author Correction: Repeat dose of NRPT (nicotinamide riboside and pterostilbene) increases NAD+ levels in human safely and sustainably: a randomized, double-blind, placebo-controlled study"		
555	9/2/2017	Email from W. Christopher to D. Alminana, C. Castro, E. Marcotulli and L. Guarente		
556	3/11/2019	Excel titled "Deferred Financing Cost Amortization - LOC (Updated 06302018)"		
557	3/11/2019	PDF titled "CDXC Investor Presentation March 2019 FINAL"		
558	2/9/2018	Email from current manufacturer to M. Morris and R. Padilla		
559	8/30/2017	Email from M. Morris to current manufacturer and Magida		
560	9/12/2017	Email from current manufacturer to M. Morris and R. Padilla		
561	10/13/2017	Current manufacturer Invoice to Elysium		

Trial Exhibit List - Dated 9/11/2019

Exhibit No.	Date	Description	Date Identified	Date Admitted
562	9/20/2017	Email from current manufacturer to M. Morris		
563	12/14/2017	Email from current manufacturer		
564	3/10/2018	Email from current manufacturer to A. Marinescu and R. Padilla		
565	3/4/2019	Subpoena to Testify issued to current manufacturer		
566	5/22/2017	Email from M. Morris to current manufacturer		
567	6/1/2017	Email from current manufacturer to M. Morris		
568	6/28/2017	Email from current manufacturer to M. Morris		
569	6/29/2017	Email from current manufacturer to M. Morris		
570	7/29/2017	Email from current manufacturer to M. Morris		
571	7/31/2017	Email from M. Morris to current manufacturer		
572	11/27/2017	Email from current manufacturer to M. Morris and D. Magida		
573	9/27/2017	Email from M. Morris to D. Magida and current manufacturer		
574	7/6/2017	Email from M. Morris to current manufacturer		
575	7/11/2017	Email from M. Morris to current manufacturer		
576	9/20/2017	Email from R. Padilla to current manufacturer		
577	6/28/2017	Email from M. Morris to current manufacturer		
578	11/28/2017	Email from current manufacturer to M. Morris		
579	1/17/2018	Email from current manufacturer to M. Morris		
580	7/7/2017	Email from M. Morris to current manufacturer		
581	8/8/2017	Email from M. Morris to current manufacturer		
582	6/5/2018	Email from R. Padilla to current manufacturer		
583	9/13/2018	PDF titled: "Certificate of Analysis/Compliance Lot # 18-527-004"		
584	5/26/2016	ChromaDex and Elysium's pTeroPure Supply Agreement		
585	2/3/2014	PDF titled "Supply Agreement between ChromaDex and Elysium"		
586	12/11/2017	Email from current manufacturer to M. Morris , D. Magida		
587	1/24/2018	Email from current manufacturer to M. Morris		
588	2/3/2014	PDF titled "Supply Agreement between ChromaDex and Elysium"		
589	9/7/2016	Email from D. Alminana to E. Marcotulli		
590	2/19/2016	PDF titled "Amendment to Supply Agreement"		
591		Text Messages		
592		Text Messages		

Trial Exhibit List - Dated 9/11/2019

Exhibit No.	Date	Description	Date Identified	Date Admitted
593		Text Messages		
594	8/12/2016	Email from Alminana to Marcotulli re NR Forecast		
595		Text Messages		
596	6/23/2016	Email from D. Alminana to M. Morris, E. Marcotulli		
597	6/23/2016	Email from M. Morris to D. Alminana, E. Marcotulli		
598	11/24/2017	IdeaMensch article "Eric Marcotulli – CEO of Elysium Health"		
599		Text Messages		
600	11/9/2013	Email with attachment from E. Marcotulli to J. Jaksch, Prag, D. Alminana, L. Guarente		
601		Text Messages		
602		Text Messages		
603	6/14/2016	PDF titled "Mututal Confidential Disclosure Agreement"		
604	6/27/2016	Email from D. Alminana to M. Morris, E. Marcotulli		
605	5/30/2016	Excel titled "NR Favored Pricing"		
606	5/30/2016	Email from J. Jaksch to D. Alminana, E. Marcotulli		
607	6/13/2016	Email from J. Jaksch to D. Alminana, E. Marcotulli		
608		Text Messages		
609	6/30/2016	Email from E. Marcotulli to D. Almiana		
610		Text Messages		
611	1/17/2018	Email from E. Marcotulli to D. Alminana, D. Fiaklow and J. Manz		
612	7/14/2016	Email from Morris to D. Alminana and E. Marcotulli		
613	7/9/2016	Email from E. Marcotulli to M. Morris		
614	7/18/2016	Excel titled : "NR Ingredient Sales Data for all customers.xlsx"		
615	7/27/2016	Email from E. Marcotulli to R. Thonemus		
616	6/22/2016	Email from M. Morris to D. Alminana and E. Marcotulli		
617	6/23/2016	Email from M. Morris to D. Alminana and E. Marcotulli		
618	8/26/2016	Email from A. Ilani to E. Marcotulli		
619	9/29/2016	Email from E. Marcotulli to A. Ilani		
620	5/1/2017	Email with attachments from D. Magida to R. Padilla		
621	10/9/2017	Email with attachment from D. Magida to R. Padilla and T. Wilhelm		

Trial Exhibit List - Dated 9/11/2019

Exhibit No.	Date	Description	Date Identified	Date Admitted
622	6/5/2018	Email with attachments from R. Padilla to current manufacturer, J. Robinson and M. Morris		
623	7/24/2018	Current manufacturer GMP Audit Report		
624	8/3/2017	Email from M. Morris to R. Padilla		
625	8/29/2017	Email with attachment from M. Morris to K. Kohan, R. Padilla		
626	9/19/2017	Email from M. Patel to R. Padilla, K. Kohan, S. Hechter and A. Slusarczyk		
627	9/22/2017	Gibraltar Laboratories, Method Transfer for Determination of Residual Acetamide in Icotinamide Riboside Chloride by GC		
628	9/29/2017	Gibraltar Laboratories, Protocol Amendment #1		
629	10/10/2017	Email from K. Kohan to R. Padilla, S. Hechter		
630	10/5/2017	Email from S. Hechter to R. Padilla, K. Kohan		
631	10/10/2017	Gibraltar eFINAL REPORT		
632	10/4/2017	Accuracy Report		
633	12/26/2017	Email with attachment from M. Morris to R. Padilla, E. Marcotulli, D. Alminana and T. Wilhelm		
634	10/10/2017	Gibraltar eFINAL REPORT		
635	6/29/2016	Email from D. Alminana to F. Jaksch, T. Rhonemus, T. Varvaro, M. Morris, C. Villalobos, E. Marcotulli		
636	6/30/2016	Email from D. Alminana to F. Jaksch, T. Rhonemus, T. Varvaro, M. Morris, C. Villalobos, E. Marcotulli, W. Black		
637	4/22/2016	Email from J. Lee to T. Varvaro		
638	10/20/2016	Email from T. Varvaro to R. Fried, N. Kotsikos		
639	7/15/2015	Email from F. Jaksch to J. Lee, T. Varvaro		
640	12/13/2013	Email from F. Jaksch to E. Marcotulli, D. Alminana, B. Prag		
641	8/11/2016	Email with attachment from W. Black to T. Varvaro, T. Rhonemus, F. Jaksch		
642	8/12/2016	Email from W. Black to D. Alminana, E. Marcotulli, F. Jaksch, T. Varvaro and T. Rhonemus		
643	8/18/2016	Email from W. Black to D. Alminana, E. Marcotulli, T. Rhonemus, F. Jaksch and T. Varvaro		
644	8/21/2016	Email from F. Jaksch to D. Alminana, W. Black, E. Marcotulli, T. Rhonemus and T. Varvaro		

Exhibit No.	Date	Description	Date Identified	Date Admitted
645	9/26/2016	Email from T. Varvaro to W. Black, T. Varvaro, F. Jaksch and T. Rhonemus		
646	12/1/2016	Email with attachment from G. Horn to F. Jaksch and W. Black		
647		Text Messages		
648		Text Messages		
649		Ryan Dellinger ChromaDex Confidentiality and Non-Solicitatoin Agreement		
650	1/10/2016	Ryan Dellinger Annual Performance Evaluation		
651	7/15/2015	Email with attachments from R. Dellinger to L. Guarente		
652	6/1/2015	Email from E. Marcotulli to R. Dellinger		
653	1/11/2016	Email from R. Dellinger to M. Marcotulli, M. Morris, D. Alminana, G. Wang and L. Guarente		
654	8/26/2015	Email with attachments from R. Dellinger to M. Marcotulli, M. Morris and D. Alminana		
655		Text Messages		
656	7/22/2016	Email with attachments from D. Alminana to R. Dellinger and E. Marcotulli		
657		Text Messages		
658	9/9/2016	Email from R. Dellinger to D. Alminana, L. Guarente, E. Marcotulli, G. Wang and M. Morris		
659	1/7/2017	Email with attachments from R. Dellinger to D. Alminana, M. Morris, E. Marcotulli		
660	10/28/2016	Email from R. Dellinger to R. McQuate, L. Brown, W. Rowe, J. Baisley, R. Butt, M. Morris		
661	1/17/2017	Exhibit A to Statement of Work between Elysium and GRAS Associates		
662	1/23/2017	Invoice from GRAS Associates to Elysium		
663	8/14/2016	Email from R. Dellinger to J. Estrela		
664	11/5/2016	Email from J. Estrela to R. Dellinger		
665	8/29/2017	Email from R. Dellinger to E. Marcotulli		
666	9/29/2016	Email from M. Morris to D. Alminana, E. Marcotulli and R. Dellinger		
667	11/12/2016	Email from M. Morris to E. Marcotulli, D. Alminana, S. Roel Santos and R. Dellinger		
668	4/25/2019	Email from R. Dellinger to M. Morris, E. Marcotulli and D. Alminana		
669	2/25/2016	Email with attachments from J. Robles to A. Shargh		
670	2/26/2016	Receipt & Acknowledgement of Employee Handbook (Employer Copy)		
671		ChromaDex PowerPoint Presentation		

Trial Exhibit List - Dated 9/11/2019

Exhibit No.	Date	Description	Date Identified	Date Admitted
672	4/5/2016	Email with attachment from M. Morris to D. Alminana, E. Marcotulli		
673	4/29/2016	Email from E. Marcotulli to M. Morris and D. Alminana		
674	6/23/2016	Email from M. Morris to D. Alminana and E. Marcotulli		
675	7/13/2016	Email from M. Morris to F. Jaksch and T. Rhonemus		
676	7/15/2016	Separation Checklist for Mark Morris		
677	7/15/2016	ChromaDex, Inc. Confidentiality and Non-Solicitation Agreement for Mark Morris		
678		PDF titled "Laurus Ptero"		
679	1/13/2017	Email from M. Moreno to C. Kruger, D. Ward, T. Rhonemus and D. Conze		
680		Excel titled "02.2016, 2017, 2018 Elysium Health Financials"		
681	3/1/2019	Invoice issued to Elysium by contract manufacturer		
682	02/00/2018	PowerPoint titled "Board of Directors Update"		
683	7/22/2016	Email from D. Magida to D. Alminana		
684	10/10/2013	Email with attachment from B. Prag to F. Jaksch		
685	2/5/2016	Email from C. Villalobos to D. Alminana, M. Morris and E. Marcotulli		
686	9/4/2016	Email from B. Reynolds to D. Alminana, L. Guarente and E. Marcotulli		
687	12/20/2013	Email from F. Jaksch to E. Marcotulli, D. Alminana, B. Prag and L. Guarente		
688	2/3/2014	Trademark License and Royalty Agreement		
689	10/14/2015	Email from M. Morris to D. Alminana and E. Marcotulli		
690		Excel titled "Acetamide Allegations 20180319"		
691		PowerPoint titled "Growth Path Analysis 6 2019"		
692		PDF titled "Summary report Acetamide GC MS FID"		
693		Excel titled "NR Shipments to CMO's 2017 and 2018"		
694		PDF titled "Tru Niagen Supplement User Prospect Survey Report 2-28-2019v3"		
695	8/19/2010	Horizontal Merger Guidelines		
696		ChromaDex Ingredients Brand Use Guidelines		
697		Compilation of ChromaDex employee confidentiality agreements		
698		Compilation of ChromaDex ingredient customer confidentiality agreements		
699		Compilation of ChromaDex Material Transfer agreements		
700		Compilation of ChromaDex confidentiality agreements with other organizations		
701				
702				

Exhibit No.	Date	Description	Date Identified	Date Admitted
703	10/10/2017	PDF titled "e-Final Report; GC Chemistry on Live Cell Research NR-1"		
704	12/22/2017	PDF titled "e-Final Report; GC Chemistry on Live Cell Research NR-1"		
705	11/9/2017	PDF with handwritten notes titled "Final Report; GC Chemistry on BPI Sports Niagenix"		
706	11/8/2017	PDF titled "TotalChrom Sequence File"		
707	11/9/2017	PDF titled with handwritten notes titled "Acetamide Residual"		
708	11/9/2017	PDF titled "Chromatogram"		
709	10/10/2017	PDF titled "Final Report; GC Chemistry; West Chemistry on Rejuvenation Niasun"		
710	10/11/2017	PDF with handwritten notes titled "System suitability results"		
711	10/11/2017	PDF with handwritten notes titled "Results for Determination of Residual Acetamide"		
712	10/4/2017	PDF with handwritten notes titled "TotalChrom Sequence File"		
713	10/5/2017	PDF with handwritten notes titled "System Suitability Summary RReport"		
714	10/9/2017	PDF with handwritten notes titled "Chromatogram"		
715	10/9/2017	PDF with handwritten notes titled "Acetamide Residual"		
716	10/7/2017	PDF with handwritten notes titled "TotalChrom Sequence File"		
717	10/8/2017	PDF with handwritten notes titled "Acetamide Residual"		
718	10/8/2017	PDF titled "Chromatogram"		
719	10/8/2017	PDF with handwritten notes titled "Acetamide Residual"		
720	10/8/2017	PDF with handwritten notes titled "Chromatogram"		
721	10/11/2017	PDF titled "TotalChrom Sequence File"		
722	10/11/2017	PDF with handwritten notes titled "Acetamide Residual"		
723	10/11/2017	PDFs titled "Chromatogram" and "Acetamide Residual"		
724	10/10/2017	PDF with handwritten notes titled "Chromatogram"		
725	10/12/2017	PDF with handwritten notes titled "Chromatogram"		
726	10/4/2017	PDF titled "Proposed Sequence for Method Transfer"		
727	9/9/2017	PDF with handwritten notes titled "Method Verification results"		
728		Opening Expert Report of Lance Gunderson		
729		Rebuttal and Supplemental Expert Report of Lance Gunderson		
730		Opening Expert Report of Iain Cockburn & Exhibits		
731		Rebuttal Expert Report of Iain Cockburn		
732		Opening Expert Report of Dr. Carla Kagel		

Exhibit No.	Date	Description	Date Identified	Date Admitted
733		Supplemental Expert Report of Dr. Carla Kagel		
734		Expert Report of Randal Heeb		
1000		2-19-2018-ChromaDex's 2nd Supplemental and Supplemental Responses to Elysium Health, Inc.'s First Set of Interrogatories		
1001		Excel Spreadsheet		
1002		12-8-2016-Letter from Heather Van Blarcom to Parshad Tafazzoli-Notice of Late Payment under the Niagen Supply Agreement, as amended		
1003		12-15-2016 -Letter from Heather Van Blarcom to Parshad Tafazzoli-Re-Notice of Termination of the Niagen Supply Agreement, as amended		
1004		1-13-2016-Letter from James Lee to 5Linx Enterprises, Inc.		
1005		12-13-2017-Settlement Agreement and General Release-between Jarrow Formulas and ChromaDex		
1006		1-25-2018-Settlement Agreement and General Release between Pretiva LLC and ChromaDex		
1007		2-9-2017-Letter from Heather Van Blarcom to David Nectar7 LLC		
1008		3-22-2017-Letter from Heather Van Blarcom to David Nectar7 LLC -Notice of Termination of the Niagen Supply Agreement, as amended		
1009		3-25-2016-Email from Frank Jaksch to Collene Villalobos-re-LIEF PO Number 55655		
1010		ChromaDex, Inc. v. Elysium Inc. -ChromaDex Privilege Log-Volume 1		
1011		6-13-2016-Email from Frank Jaksch to Dan Alminana-Re-Wired Magazine and NR Questions		
1012		9-9-2014- E-mail from Leonard Guarente to Robert Fried-Re-Introduction		
1013		10-30-2016-E-mail from Frank Jaksch to Dan Alminana-Re-Call today or tomorrow		
1014		10-31-2016- E-mail from Frank Jaksch to Stephen Block-Elysium Health Supply Agreement 2-3-2014		
1015		10-31-2016-E-mail from F.Jaksch to Stephen Block-Re-FW-Call and Royalty Report		
1016		10-31-2016-Email from Frank Jaksch to Stephen Block-Re-FW-Call and Royalty Report		
1017		10-31-2016-E-mail from Frank Jaksch to Stephen Block-FW-Call and Royalty Report		
1018		10-31-2016-Email from Frank Jaksch to Stephen Block-Re-FW-Call and Royalty Report		

Trial Exhibit List - Dated 9/11/2019

Exhibit No.	Date	Description	Date Identified	Date Admitted
1019		10-31-2016 E-mail from Frank Jaksch to Stephen Block-FW Follow-up		
1020		10-31-2016-E-mail from Frank Jaksch to Stephen Block-FW Follow-up		
1021		10-31-2016-E-mail from Frank Jaksch to Stephen Block-Re-FW Letters Regarding Breaches		
1022		11-1-2016-E-mail from Frank Jaksch to Dan Alminana; Eric Marcotulli-Re-Agreement Non-Renewal Letter		
1023		11-3-2016-E-mail from Frank Jaksch to Dan Alminana; Stephen Block-Re-Discussion		
1024		11-8-2016-E-mail from Stephen Block to Robert Fried-Re-Proposal		
1025		11-20-2016 E-mail to Jeff Baxer; Steve Allen; Stephen Block; Robert Fried; Kurt Gustafson-Re-CDXC DTC Channel Development: Discussion Paper		
1026		11-19-2016-E-mail from Frank Jaksch to Stephen Block; Steve Allen-Re-First Draft of terms for HS agreement		
1027		Spreadsheet Text Messages		
1028		E-mail to Jeff Baxer; Kurt Gustafson; Robert Fried; Steve Allen; Stephen Block-Re-Options		
1029		12-8-2016-E-mail from Stephen Block to Robert Fried-Re-Term Sheet		
1030		12-8-2016-E-mail from Robert Fried to Stephen Block-Re-Term Sheet		
1031		12-9-2016-Email from Stephen Block to Robert Fried-Re-Transaction Term Sheet		
1032		12-10-2016-Email from Stephen Block to Tom Varvaro-Re-Fwd: Potential Aquisiton of Healthspan and Employment of Robert Fried		
1033		12-11-2016-E-mail from Tom Varvaro to Stephen Block-Re-Potential Acquisition of Healthspan and Employment of Robert Fried		
1034		12-11-2016-E-mail from Stephen Block to Tom Varvaro-Re-Potential Acquisition of Healthspan and Employment of Robert Fried		
1035		3-11-2017=E-mail from Tom Varvaro to Frank Jaksch; Stephen Block; Steve Allen; Jeff Baxter; Kurt Gustafson; Robert Fried Re-FW Valuation Draft		
1036		SEC Form 8-K - ChromaDex Corporation Dated July 9, 2015		
1037		12-6-2016-E-mail from Michael Brauser to Frank Jaksch-Re-Call		
1038		12-7-2016-E-mail from Michael Brauser to Dan Alminana-Re-Need to Call to reslove issue		

Exhibit No.	Date	Description	Date Identified	Date Admitted
1039		12-7-2016-Email from Michael Brauser to Barry Honig; John Stetson; Josh O'Rourke-FW: Elysium		
1040		12-7-2016-E-mail from Michael Brauser to Geoffery Harrison-Re-(Redacted)		
1041		1-14-2019-ChromaDex, Inc's Supplemental Initial Disclosures Pusuant to Fed. R. Civ. P. 26(A)		
1042		9-25-2015-E-mail from Aron Erickson to Troy Rhonemus-Re- QUB Experimental Index		
1043		1-21-2016-E-mail from Aron Erickson to Derik Ward; Rich Nygaard-Re-Status Meeting-PRJT0002-Pilot Plant Initial Development and Start-Up Project		
1044		10-4-2016-E-mail from Derik Ward to Claire Kruger, Nicole Beucahmp, Dietrich Conze, Troy Rhonemus; Matthew Moreno and Aron Erickson		
1045		10-7-2016-E-mail from K. Brailer to Claire Kruger cc: Aron Erickson-Re-pIND 130695 FDA Correspondence		
1046		1-14-2017-E-mail from Troy Rhonemus to Derik Ward; Aron Erickson and Matthew Moreno-Re-Pharma Product and Acetamide Testing of Niagen Batches		
1047		1-19-2017-E-mail from Derik Ward to Claire Kruger; Amy Boileau; Dietrich Conze; Matthew Moreno; Aron Erickson; Nicole Beauchamp and Troy Rhomemus-RE-Niagen Batch Statuses and GRAS Change Request/Amendment		
1048		1-24-2017-E-mail from Derik Ward to Adriana Torres and Aron Erickson-Re-Niagen Lot # 16209-21 status, QA process and freezer storage		
1049		1-24-2017-E-mail from Dietrich Conze to Derik Ward; Claire Kruger; Matthew Moreno and Aron Erickson-Re-Acetamide Spec for Niagen		
1050		1-27-2017-E-mail from Aron Erickson to Claire Kruger; Derik Ward; Matthew Moreno, Dietrich Conze and Amy Boileau-Re-Identifying a pharma batch for dog study and solvent levels		
1051		1-27-2017-Email from Derik Ward to Claire Kruger; Dietrich Conze; Nicole Beauchamp; Yuting Zhou; Aron Erickson; Matthew Moreno; Amy Boileau and Troy Rhonemus-Re-Niagen Lots and Acetamide testing-Regulatory Review Meeting		
1052		1-31-2017-Email from Adriana Torres to Derik Ward; Aron Erickson; David Clarke; Kiel Henderson and Hadi Cassier-Re-Niagen Lot # 16203-21 and 16204-21 status, QA process and freezer storage		

Exhibit No.	Date	Description	Date Identified	Date Admitted
1053		2-3-2017-E-mail from Derik Ward to Matthew Moreno; Aron Erickson and Kiel Henderson-Re-NR Analytics Review-Stability, Purity, AA, Acetamide, etc		
1054		3-9-2017-E-mail from Derik Ward to Matthew Moreno; Troy Rhonemus and Aron Erickson-Re-Need for Grace Meeting-possibly Face to Face		
1055		4-11-2017-E-mail from Derik Ward to Aron Erickson; Matthew Moreno; Brian Graves; Erik Carlson; Deron Neukomm; Jerry O'Bannon; Jose Osuna; Heidi Shrewsbury; Reddy Nandipati ccing Derik Ward and Troy Rhonemus Re-Prep and Agenda for Grace and ChromaDex Weekly Process Imp and Production Meeting		
1056		4-11-2017-E-mail from Derik Ward to Aron Erickson-Re-FW: Acetamide Fact Sheet for Troy		
1057		4-20-2017-Email from Aron Erickson to Troy Rhonemus -Re- Emailing NRCI Data.xlsx		
1058		5-5-2017-Email from Derik Ward to Matthew Moreno; Aron Erickson and Troy Rhonemus-Re-Touchbase on progress with Grace		
1059		7-3-2017-E-mail fro Derik Ward to Aron Erickson-Re- Need 1 kg samples send to Longemont for research		
1060		10-18-2017-E-mail from T. Rhonemus to Derik Ward; Amy Boileau and Aron Erickson-Re-Grace for today's call		
1061		5-8-2017 -Spreadsheet-Author Derik Ward-Specs for Grace		
1062		7-7-2017 E-mail from Aron Erickson to Derik Ward-Re-Acetamide results from Grace Sample		
1063		5-22-2017-E-mail from Derik Ward to David Clarke; Matthew Moreno and Aron Erickson-Re-More Acetamide Testing needed for Niagen		
1064		ChromaDex Standard Operating Procedure-Confidential-Acetamide Impurity Analysis in NR-CI by GC-FID -8-24-2017		
1065		ChromaDex Standard Operating Procedure-Confidential - Acetamide Impurity Analysis in NR-CI by GC-FID-1-15-2018		
1066		Form 8K for ChromaDex-Date of Report-1-8-2018		
1067		Bio of Troy Rhonemus-from ChromaDex website		
1068		1-14-2019-ChromaDex's Supplemental Initial Disclosures		
1069		CDC Fifth Amended Complaint-dated 11-27-2018		

Trial Exhibit List - Dated 9/11/2019

Exhibit No.	Date	Description	Date Identified	Date Admitted
1070		Exhibit C to CDC Fifth Amended Complaint-dated 11-27-2018-(Supply Agreement between ChromaDex and Elysium-dated 2-3-2014)		
1071		Exhibit D to CDC Fifth Amended Complaint-dated-11-27-2018- (Amendment to Supply Agreement between ChromaDex and Elysium-dated 2-19-2016)		
1072		1-28-2015 E-mail from Troy Rhonemus to Audrey Kelleman; Frank Jaksch; Brett Reynolds and Dan Fabricant-Re-21 CFR 110 vs 111		
1073		2-17-2016-Email from Troy Rhonemus to Dan Alminana-Re-NR+ Ptero Exclusivity-Amendment to Supply Agreement		
1074		1-8-2016-E-mail from Troy Rhonemus to Tom Varvaro and Heather Van Blarcom-Re-Happy New Year		
1075		8-2-2013-E-mail from Troy Rhonemus to Tom Varvaro-Re-Additional DD questions set 2		
1076		12-7-2013- E-mail from Troy Rhonemus to Mark Morris-Niagen Supply Agreement		
1077		3-5-2014-E-mail from Troy Rhonemus to Rae Miller; Mark Morris and David Seid-Re-Niagen Agreement		
1078		4-17-2015-E-mail from Troy Rhonemus to Tom Varvaro-Re-Supply Agreement NIAGEN NeutriSci 041615 (2)		
1079		3-25-2016-E-mail from Collene Villalobos to Troy Rhonemus and Frank Jaksch-Re- Fwd: LIEF PO Number 55655		
1080		7-2-2015-E-mail from Teddy Klinghoffer to Heather Van Blarcom-Re-FW: HealthSpan Research LLC Agreement		
1081		7-16-2015-E-mail from Heather Van Blarcom to Teddy Klinghoffer-Re- Healthspan Research Insterest Purchase Agreement		
1082		8-28-2015-E-mail from Heather Van Blarcom to Troy Rhonemus-Re-FW: Executed Documents: Healthspan Research LLC		
1083		5-25-2016-E-mail from Collene Villalobos to Troy Rhomemus and Will Black-Re-Niagen-MAP Pricing		
1084		5-31-2016-e-mail from Troy Rhonemus to Frank Jaksch- Attachment-Elysium Health Supply Agreement 2.3.14		
1085		6-13-2016-E-mail from Frank Jaksch to Troy Rhonemus-NR Supply Agreements Summary for Elysium 06.13.2016		

Exhibit No.	Date	Description	Date Identified	Date Admitted
1086		9-23-2016-E-mail from Troy Rhonemus to Will Black-Re- Niagen and pTeroPure for Elysium		
1087		11-15-2016-E-mail sent to Troy Rhonemus-Re-2017 Sales and Marketing Budget		
1088		2-13-2015-E-mail from Claire Kruger to Juan Crespo-Barreto; Dave Short and Audrey Kelleman-Re-Acetamide level		
1089		2-13-2015-E-mail from A. Kellemant to Troy Rhonemus; Juan Crespo-Barreto and Dave Short-Re-Acetamide level		
1090		1-13-2017-Email from Troy Rhonemus to Claire Kruger-Re-Niacin Project: Need Information for the 7-Day Puppy Study (Draft Protocol)		
1091		1-13-2017-E-mail from Troy Rhonemus to Claire Kruger-Re-Niacin Project-Need Information for the 7-Day Puppy Study (Draft Protocol)		
1092		3-24-2017-E-mail from Derik Ward to Brett Reynolds; Troy Rhoenmus and Matthew Moreno-Re-Meeting between ChromaDex and Grace-first week of April?		
1093		3-30-2017-E-mail from Brett Reynolds to Troy Rhonemus-Re-Niagen		
1094		5-19-2017-E-mail from Derik Ward to T. Rhomemus-Re-Grace hitting our acetamide spec		
1095		7-7-2017 E-mail from Derik Ward to Aron Erickson; Matthew Moreno and Troy Rhonemus-Re-Grace update and decisions		
1096		7-29-2017 E-mail from Derik Ward to Troy Rhonemus-Re-Status of Grace quality agreement and spec agreement-170729		
1097		SEC Form 8K for ChromaDex Corporation-Date of Report 6-20-2008		
1098		SEC Filing-Form-for ChromaDex Corporation-Schedule 14A		
1099		SEC Form 8K for ChromaDex Corporation-Date of Report 10-4-2017		
1100		SEC Form 10-Q-ChromaDex Corporation-for the quarterly period ended September 30, 2017		
1101		SEC Form 8K for ChromaDex Corporation-Date of Report 12-15-2017		
1102		1-9-2016-E-mail from Erin Swick to Heather Van Blarcom-Re- #36995134v6 Active -BPI Sports-Supply Agreement ChromaDex cdx comments		
1103		1-9-2014-E-mail from Barry Kaufman to Tom Varvaro-Re-W-Deren-Lewis v. ChromaDex/Jaksch, et al		
1104		11-6-2015-E-mail from James Lee to Tom Varvaro-Re-Elysium-New Order		

Exhibit No.	Date	Description	Date Identified	Date Admitted
1105		4-1-2016-E-mail from Eric Marcotulli to Mark Morris and Dan Alminana-Re-Purchase Orders		
1106		4-1-2016-E-mail from Collene Villalobos to Tom Varvaro-Re-Elysium Payment Terms		
1107		6-28-2016-E-mail from Dan Alminanato Frank Jaksch; Troy Rhonemus; Tom Varvaro; Mark Morris, Collene Villalobos-Re- Purchase Orders		
1108		6-30-2016-E-mail from Frank Jaksch to Dan Alminana-Re- Purchase Orders		
1109		6-30-2016-e-mail from Dan Alminanato Frank Jaksch-Re-Purchase Orders		
1110		5-12-2015-E-mail from Tom Varvaro to H. Van Blarcom-Draft term sheet		
1111		5-21-2015-E-mail from Tom Varvaro to Frank Jaksch-Re-Rob Fried Supply Agreement		
1112		8-10-2015-E-mail from Tom Varvaro to Erin Swick		
1113		9-29-2015-E-mail from Troy Rhonemus to Tom Varvaro-Re-FW-Exxecuted Documents: Healthspan Research LLC		
1114		1-27-2016-E-mail from Tom Varvaro to Frank Jaksch-Attachment-Healthspan Research Supply Agreement 8-27-2015		
1115		9-16-2016-E-mail from Tom Varvaro to Frank Jaksch-Re-FW: Healthspan Memo		
1116		9-27-2016-E-mail from Tom Varvaro to Frank Jaksch-Re-FW-Rob F.		
1117		12-10-2016-E-mail from Stephen Block to Steve Allen; Jeff Baxer; Kurt Gustafson-Re-Potential Acquisition of Healthspan and Employment of Rob Fried		
1118		12-10-2016-E-mail from Stephen Block to Tom Varvaro-Re- Fwd: Potential Acquisition of Healthspan and Employment of Rob Fried		
1119		12-11-2016-E-mail from Tom Varvaro to James Lee-Re-FW: Potential Acquisition of Healthspan and Employment of Rob Fried		
1120		3-10-2017-E-mail from M. Robbins to Frank Jaksch and Tom Varvaro-Re-Executed Healthspan Documents		
1121		3-11-2017-E-mail from Tom Varvaro to Frank Jaksch; Stephen Block; Steve Allen; Jeff Baxer; Kurt Gustafson and Robert Fried-Re FW-Valuation Draft		
1122		3-16-2017-Email from Frank Jaksch to Andrew Johnson-Re- FW-ICR's input on our Customer Talking Points		

Exhibit No.	Date	Description	Date Identified	Date Admitted
1123		4-6-2017-E-mail from James Lee to Tom Varvaro-Re-Memo-Healthspan Acquisition Accounting Treatment		
1124		4-7-2017-E-mail from James Lee to Dave Horin and Philip Hood-Re-Accounting Treatment-Asset Purchase		
1125		4-11-2017-E-mail from Tom Varvaro to James Lee-Re- Valuation Draft		
1126		4-18-2017-E-mail from Tom Varvaro to Will Black and Andrew Johnson-Re-FW-Valuation Draft		
1127		5-22-2017-E-mail from James Lee to Tom Varvaro-Re-Royaltys		
1128		3-1-2016-E-mail from Tom Varvaro to Troy Rhonemus-Re- Book1.xlsx		
1129		1-17-2017-E-mail from Tom Varvaro to James Lee-Re- FW: 2017 Budget		
1130		1-26-2016-E-mail from Tom Varvaro to Troy Rhonemus-FW-Niagen License Agreement		
1131		8-14-2016-E-mail from Tom Varvaro to James Lee-Re- Q2 2017 NR Royalties to Universities		
1132		8-11-2016-E-mail from James Lee to Tom Varvaro-Re-Elysium Pricing		
1133		12-12-2016-E-mail from Amy Boileau to Claire Kruger and K. Brailer-Re Elysium Contact		
1134		1-19-2017-E-mail from Matthew Moreno to Derik Ward and Amy Boileau-Re-Niagen Batch Statuses and GRAS Spec Change Request/Amendment		
1135		4-11-2017-Email from Amy Boileau to Derik Ward-Re-FW: Acetamide Fact Sheet for Troy		
1136		4-11-2017-Email from Derik Ward to Amy Boileau-Re: Acetamide Fact Sheet for Troy		
1137		4-21-2017-E-mail from Amy Boileau to Amy Boileau and Derik Ward-Re-Conversation between Amy Boileau and Derik Ward		
1138		6-20-2017-E-mail from Amy Boileau to Troy Rhonemus; Derik Ward, Claire Kruger; Frank Jaksch; Will Black; Aron Erickson and Robert Fried-Re-Nestle Health Science Presentation		
1139		8-17-2019-E-mail from Amy Boileau to Derik Ward and Aron Erickson-Re-The Saga Continues		

Exhibit No.	Date	Description	Date Identified	Date Admitted
1140		10-30-2017-Email from Adriana Torres to Derik Ward; Amy Boileau; C. Norman; Aron Erickson and S. Mughrabi-Re-NIAGEN Spec Comparison-COA Clean up activity		
1141		5-30-2017-E-mail from Suhad Mugharbi to Amy Boileau; Derik Ward and Matthew Moreno-Re-Exported NIAGEN		
1142		9-10-2017-E-mail from Amy Boileau to Breah Ostendorf; Frank Jaksch; Robert Fried and Troy Rhonemus-Re-Citizen Petition Release DRAFT clean		
1143		6-20-2016-E-mail from Frank Jaksch to Andrew Johnson and Tom Varvaro-Re-PR Response		
1144		6-24-2016-E-mail from Frank Jaksch to Stephen Block and Tom Varvaro-Re-8-K Logistics and Timing		
1145		6-24-2016-E-mail fro Stephen Block ot Frank Jaksch-Re-8-K Logistics and Timing		
1146		11-9-2013 E-mail from Frank Jaksch to Tom Varvaro-Fwd: Partnership Agreement-Draft		
1147		4-2-2016- For the quarterly period ended- SEC From 10-Q-ChromaDex Corporation		
1148		9-16-2016-E-mail from Paul Jacobson to Will Black; Frank Jaksch and Troy Rhonemus-Re-Comment on the note and our conversation		
1149		9-4-2015 E-mail from Frank Jaksch to Tom Varvaro; Troy Rhonemus and Mark Morris-Re-Fwd: The idea of a lifetime-and he blew it		
1150		6-8-2016 E-mail from Mark Morris to Frank Jaksch-Re- Wired Magazine and NR Questions		
1151		6-29-2016-E-mail from F.Jaksch to Will Black-Re- FW: Wired Magazine and NR Questions		
1152		6-30-2016-E-mail from Will Black to Will Black; Frank Jaksch-Re-Elysium Draft		
1153		12-7-2016-E-mail from Michael Brauser to F. Carreras (General Catlayst)-Re-Elysium		
1154		4-23-2015 Email from Tom Varvaro to Frank Jaksch- Re- Draft Term Sheet		
1155		5-4-2015-E-mail from Tom Varvaro to Frank Jaksch-Re- Draft term sheet		
1156		11-20-2016-E-mail from Stephen Block to Frank Jaksch-Re- HS Document		
1157		12-10-2016-E-mail from Stephen Block to Frank Jaksch-Re-Fwd; Healthspan Acquisition/Rob Fried Employment		

Exhibit No.	Date	Description	Date Identified	Date Admitted
1158		12-10-2016-E-mail from Stephen Block to Frank Jaksch-Re- Fwd: Healthspan Acquisition/Rob Fried Employment		
1159		3-27-2017-Email from James Lee to N. Marckwordt-Re- ChromaDex-New Share Issuance		
1160		12-27-2016-E-mail from Natalie Mikolich to Frank Jaksch and Will Black-Re- Quick Questions from Tech Crunch		
1161		12-8-2017-ChromaDex Press Release-NR shown to Improve Mitochondrial Energy Production and Memory in Alzheimer's Disease Research		
1162		SEC Form 6-K-Tiger Media, Inc.		
1163		4-24-2015-E-mail from Frank Jaksch to Robert Fried-Re-Draft term sheet		
1164		6-11-2015-E-mail from Dan Alminanato Rob F.-Re: Checking In		
1165		1-5-2016-E-mail from Charles Brenner to Robert Fried-Re-Fwd: Annual Conflict of Interest Disclosure Requirement		
1166		1-6-2016-E-mail from Rob F. to Cheryl Romano; Rachel Farabaugh, Charmaine Lacewell; Patrick Thona-Re Fw: Label		
1167		1-21-2016-E-mail from Robert Fried to rob@spiritclips.com-Re- Fw: Amendment to the Agreement		
1168		1-18-2016-E-mail from Charles Brenner to Robert Fried-Fwd: Healthspan Website Copy for Review		
1169		1-24-2016-E-mail from Cheryl Romano to Robert Fried-Re-Fwd: Healthspan Website Copy for Review		
1170		1-24-2016-E-mail from Charles Brenner to Robert Fried-Re-Healthspan Website Copy for Review		
1171		2-7-2016-E-mail from Charles Brenner to Robert Fried-Re-Healthspan Research agreement		
1172		7-31-2015 to 10-23-2017- Text Messages between Robert Fried and Frank Jaksch; Charles Brenner; Rudy Tanzi, Tom Coll. Yvette Holm; Sarah Goodchild; Straus Zelnick. Steve Allen; Jeff Baxer; Nicholas Kotsikos; Rob Levitan; Jeff Sechrest; Jeffery Allen and Steve Rubin		
1173		8-6-2016-E-mail from Charles Brenner to Robert Fried-Re- What does healthspan mean?		

Exhibit No.	Date	Description	Date Identified	Date Admitted
1174		11-19-2016-E-mail from Frank Jaksch to Robert Fried-Re-Draft term sheet		
1175		11-21-2016-E-mail from J. Sechrest to r Robert Fried-Re-Cornerstones for Agreement with Healthspan 11 18 2016		
1176		11-20-2016-E-mail from Frank Jaksch to Jeff Baxer; Steve Allen; Stephen Block; Robert Fried and Kurt Gustafson-Re-CDXC DTC Channel Development: Discussion Paper		
1177		11-22-2016-E-mail from Frank Jaksch to Jeff Baxer; Kurt Gustafson; Robert Fried; Steve Allen; Stephen Block-Re- Options		
1178		4-8-2017-E-mail from Troy Rhonemus to Robert Fried; Frank Jaksch; Tom Varvaro-Re-Data		
1179		8-11-2017-E-mail from Frank Jaksch to Robert Fried-Re- (none)		
1180		11-30-2016-E-mail from Robert Fried to Frank Jaksch-Re: Fwd: NYC next week		
1181		7-31-2017-E-mail from N. Mikolich to Frank Jaksch; Robert Fried- Re- Latest Elysium article		
1182		8-3-2017-E-mail from Frank Jaksch; Robert Fried-Re-Elysium Picture		
1183		8-9-2017-E-mail from Breah Ostendorf to Robert Fried; Will Black; Andrew Johnson; Frank Jaksch-Re- Elysium activity summary		
1184		9-5-2017-E-mail from Breah Ostendorf to Frank Jaksch; Robert Fried; Andrew Johnson; Amy Boileau-Re- Toulene PR (002)		
1185		6-29-2016-E-mail from Frank Jaksch to Will Black-Re-FW: Wired Magazine and NR Questions		
1186		8-16-2017-Email frpm Will Black to Dan Alminana-Re- Call and Royalty Report		
1187		8-16-2016-E-mail from Tom Varvaro to Will Black-Re-FW: Call and Royalty Report		
1188		8-16-2016-E-mail from Troy Rhonemus to Will Black-Re-Call and Royalty report		
1189		8-2-1016-E-mail from Frank Jaksch to Will Black-Re-Call and Royalty Report		
1190		9-21-2016-E-mail from John Mai to Will Black-Re-Niagen pricing		
1191		10-11-2016-E-mail from Will Black to E. Somer-Re-ChromaDex news		
1192		9-8-2016-E-mail from Headley Lee to Will Black; Kevin Suarez-Re-Call to discuss product launch		
1193		9-15-2016-E-mail from Will Black to Paul Jacobson		

Exhibit No.	Date	Description	Date Identified	Date Admitted
1194		9-16-2016-E-mail from Will Black to Paul Jacobson-Re-comment on the note and our conversation		
1195		9-23-2016-E-mail from Will Black to Glenn MacEachern-Re-Follow-up to our discussion this morning		
1196		11-17-2016-E-mail from Will Black to Frank Jaksch-Re-Agreement outline-Rob Fried		
1197		11-18-2016-E-mail from Will Black to Frank Jaksch-Re- Rob Draft		
1198		12-19-2016-E-mail from Will Black to Troy Rhonemus-Re DTC Customer analysis		
1199		12-19-2016-E-mail from Will Black to Tom Varvaro; Troy Rhonemus-Re-DRC customer contribution to CDX		
1200		1-13-2017-E-mail from Will Black to Frank Jaksch-Re-FW: Sales Budget		
1201		1-17-2017-E-mail from Will Black to Tom Varvaro-Re-2017 Budget		
1202		7-11-2017-E-mail from Brian Park to Will Black-Re- NIAGEN-Korea		
1203		2-11-2019-Amended Notice of FRCP 30(b)(6) Deposition of ChromaDex, Inc.		
1204		4-8-2017-E-mail from Troy Rhonemus to Robert Fried, Frank Jaksch, Tom Varvaro-Re- Data		
1205		1-5-2017-E-mail from Jenny Robles to Tom Varvaro-Re: Ryan and Mark		
1206		2-3-2014-Trademark License and Royalty Agreement between Elysium Health and ChromaDex, Inc.		
1207		11-9-2013-E-mail from Eric Marcotulli to Frank Jaksch, Bob Prag-Re-Partnership Agreement-Draft		
1208		GRAS Notices-GRN No. 635- Date of Filing- March 29, 2016-Substance-Nicorinamide Riboside Chloride		
1209		10-3-2015 SEC-Form 10-Q- ChromaDex Corporation		
1210		6-17-2014-E-mail from Matthew Moreno to Troy Rhonemus-Re-FW: Grace Notes		
1211		5-25-2016-E-mail from Derik Ward to Aron Erickson; Matthew Moreno-Re-Develop plan and execute work to gather data needed for GRAS addendum		
1212		1-19-2017-E-mail from Amy Boileau to Matthew Moreno; Derik Ward-Re-Niagen Batch Statuses and GRAS Change Request/Amendment		
1213		1-24-2017-E-mail from Derik Ward to Dietrich Conze; Claire Kruger; Matthew Moreno; Aron Erickson-Re-acetamide spec for Niagen		

Trial Exhibit List - Dated 9/11/2019

Exhibit No.	Date	Description	Date Identified	Date Admitted
1214		1-27-2017-E-mail from Derik Ward to Claire Kruger; Dietrich Conze; Nicole Beauchamp; Yuting Zuhou; Aron Erickson; Matthew Moreno; Amy Boileau; Troy Rhonemus-Re- Niagen Lots and Acetamide testing-Regulatory Review Meeting		
1215		2-2-2017-E-mail from Derik Ward to Matthew Moreno-Re-Niagen specs for EU and NZ		
1216		2-3-2017-E-mail from Derik Ward to Matthew Moreno; Aron Erickson; Kiel Henderson-Re-Internal CDXC and Grace NR Alignment meeting		
1217		3-2-2017-E-mail from Kiel Henderson to Aron Erickson; Derik Ward; CC: Matthew Moreno-Re-GC Acetic Acid results and single point NR data updated		
1218		CA Proposition 65 Statement-Product-Nicotinamide Riboside Chloride		
1219		Email from Dan Alminana to Frank Jaksch, copying Leonard Guarente, Bob Prag, Eric Marcotulli, and Laura Carney, sent August 27, 2013		
1220		Text message sent by Frank Jaksch to Will McCamy		
1221		Form 8-K filed with the U.S. Securities & Exchange Commission ("SEC") by ChromaDex on April 19, 2018		
1222		Text message sent by Robert Fried to Dan Levitan		
1223		Form 10-K filed by ChromaDex with the SEC for the fiscal year ending December 30, 2017		
1224		ChromaDex's Answer and Counterclaims Against Novex Biotech LLC, filed on May 24, 2019 in the litigation captioned Novex Biotech, LLC v. ChromaDex, Inc., Case No. 2:19-cv-00271-JNP-PMW (D. Utah) (ECF No. 26)		
1225		Native Excel file (NR Sales, Profits, Costs and Inventory Levels)		
1226		Email and attachments from Dan Alminana to Frank Jaksch, copying Eric Marcotulli, sent June 27, 2014		
1227		Email and attachments from Dan Alminana to Collene Villalobos, copying Frank Jaksch, Mark Morris, and Eric Marcotulli, sent February 10, 2015		
1228		Email and attachments from Dan Alminana to Frank Jaksch, Mark Morris, and Collene Villalobos, copying Eric Marcotulli, sent May 27, 2015		
1229		Email and attachments from Dan Alminana to Frank Jaksch, Mark Morris, and Collene Villalobos, copying Eric Marcotulli, sent July 2, 2015		

Trial Exhibit List - Dated 9/11/2019

Exhibit No.	Date	Description	Date Identified	Date Admitted
1230		Email and attachments from Dan Alminana to Frank Jaksch, Mark Morris, and Collene Villalobos, copying Eric Marcotulli, sent October 2, 2015		
1231		Email and attachments from Dan Alminana to Frank Jaksch, Mark Morris, and Collene Villalobos, copying Eric Marcotulli, sent November 5, 2015		
1232		Email and attachments from Dan Alminana to Frank Jaksch, Troy Rhonemus, Mark Morris, and Collene Villalobos, copying Eric Marcotulli, sent February 22, 2016		
1233		Email and attachments from Dan Alminana to Frank Jaksch, Troy Rhonemus, Tom Varvaro, Mark Morris, and Collene Villalobos, copying Eric Marcotulli, sent April 1, 2016		
1234		Email from Dan Alminana to Frank Jaksch, copying Eric Marcotulli, sent May 30, 2016		
1235		Email from Dan Alminana to Frank Jaksch, copying Eric Marcotulli, sent June 13, 2016		
1236		Email and attachments from Dan Alminana to Frank Jaksch, Troy Rhonemus, Tom Varvaro, Mark Morris, and Collene Villalobos, copying Eric Marcotulli, sent June 28, 2016		
1237		Email from Frank Jaksch to Dan Alminana, copying Troy Rhonemus, Tom Varvaro, Mark Morris, Collene Villalobos, Eric Marcotulli, and Will Black, sent June 30, 2016		
1238		Email from Eric Marcotulli to Dan Alminana, sent June 30, 2016		
1239		Email from Frank Jaksch to Dan Alminana, copying Troy Rhonemus, Tom Varvaro, Mark Morris, Collene Villalobos, Eric Marcotulli, and Will Black, sent June 30, 2016		
1240		Email from Will Black to Dan Alminana, sent June 30, 2016		
1241		Form 8-K filed by ChromaDex with the SEC on July 9, 2013		
1242		Email and attachments from Tom Varvaro to Dan Alminana, Eric Marcotulli, copying Frank Jaksch, Troy Rhonemus, and Will Black, sent September 8, 2016		
1243		Email and attachment from Daniel Magida to Dan Alminana, sent June 24, 2016		
1244		“Generally Recognized As Safe (GRAS) Determination for Niagen (Nicotinamide Riboside Chloride)” filed by ChromaDex, publicly available at https://www.fda.gov/files/food/published/GRAS-Notice-000635--Nicotinamide-riboside-chloride.pdf		
1245		Email and attachment from Brett Reynolds to Troy Rhonemus, sent June 16, 2016		

Trial Exhibit List - Dated 9/11/2019

Exhibit No.	Date	Description	Date Identified	Date Admitted
1246		Email and attachment from Troy Rhonemus to Frank Jaksch, sent May 22, 2017,		
1247		Email and attachment from Mark Morris to Sean Torbati, sent June 10, 2013		
1248		Email and attachment from Katie Lowerison to Mark Morris, sent October 10, 2013		
1249		Document titled Trademark License Agreement		
1250		Email from Eric Marcotulli to Frank Jaksch, copying Dan Alminana, sent January 29, 2014		
1251		Document titled Supply Agreement (Evovled Organics)		
1252		Document titled Supply Agreement (Thrive Now Health)		
1253		Email and attachments from Laura Kelly to Will Black, sent October 21, 2016		
1254		Document titled Supply Agreement (JW Nutritional)		
1255		Document titled Supply Agreement (ProHealth)		
1256		Document titled Supply Agreement (Jarrow Formulas)		
1257		An email and attachments from Heather Van Blarcom to Will Black, Frank Jaksch, Tom Varvaro and Troy Rhonemus, sent May 1, 2017		
1258		Email and attachment from Mark Morris to Troy Rhonemus, dated August 27, 2015		
1259		Email and attachments from Headley to Mark Morris, sent April 18, 2016		
1260		Email from Dan Magida to Mark Morris, copying Dan Alminana, sent November 23, 2016		
1261		Compilation of the results for acetamide testing conducted by Gibraltar Laboratories, dated from August 2017 – December 2017		
1262		Email and attachment from Laura Kelly to Derik Ward, sent February 5, 2018,		
1263		Email and attachment from Troy Rhonemus to Audrey Kelleman, Frank Jaksch, Brett Reynolds, and Daniel Fabricant, sent January 28, 2015		
1264		Letter sent via email from Michael Powell (former counsel for Elysium) to Jon Cieslak (former counsel for ChromaDex) on January 4, 2018.		
1265		Email from Collene Villalobos to Dan Alminana, copying Dan Magida, sent on July 11, 2016		
1266		Email and attachments from James Lee to SEC Connect Filing Desk, copying Tom Varvaro, sent November 9, 2016		
1267		Email and attachment from James Lee to Tom Varvaro, sent September 10, 2013		
1268		Email and attachments from Tom Varvaro to Troy Rhonemus sent July 10, 2014		

Trial Exhibit List - Dated 9/11/2019

Exhibit No.	Date	Description	Date Identified	Date Admitted
1269		Email and attachment from Laura Kelly to Frank Jaksch, Tom Varvaro and James Lee, sent May 27, 2014		
1270		Document titled Ingredients-ChromaDex		
1271		Email and attachment from Jenny Schwanky to Timothy O'Brien, copying Edward Schauder, Tom Varvaro and Frank Jaksch, sent July 12, 2013		
1272		Email and attachment from Frank Jaksch to Laura Kelly, sent August 8, 2014		
1273		Email and attachment from Fran Jaksch to Hugh Dunkerley, Jeff, Baxter, Reid Dabney, Rob Fried, Steve Allen, Steve Block and Tom Varvaro, sent on March 16, 2016		
1274		Document titled ChromaDex Investor Presentation December 2015		
1275		Email and attachment from Frank Jaksch to Karin Writes, sent June 25, 2016		
1276		Email and attachment from Scott Glowinski to Frank Jaksch, Tom Varvaro, Troy Rhonemus, Dung Nguyen, Ryan Plusch, Mark Rosenblum and Evan Barre, sent May 3, 2014		
1277		Email and attachment from Tom Varvaro to Troy Rhonemus and Frank Jaksch, sent April 23, 2014		
1278		Email and attachment from Mark Rosenblum to Frank Jaksch and Tom Varvaro, sent April 29, 2014		
1279		Email and attachment from Tom Varvaro to Troy Rhonemus and Frank Jaksch, sent April 29, 2014		
1280		Email and attachment from Troy Rhonemus to Mark Morris and Ryan Dellinger, sent April 29, 2014		
1281		Email and attachment from ChromaDex, Inc. to Andrew J, sent January 6, 2016		
1282		Email and attachment from Frank Jaksch to Deirdre Newman, sent March 2, 2016		
1283		Email from Frank Jaksch to Natalie Mikolich and Will Black, sent December 27, 2016		
1284		Email from Frank Jaksch to Mark Morris, Siva Hari, Stephen Olmstead, Shana, and Ed Hauck, sent July 25, 2014		
1285		Document titled Supply Agreement (Adept Life Science)		
1286		Document titled Trademark License Agreement (Thrive Now Health)		
1287		Document titled Trademark License Agreement (Thorne)		
1288		Email and attachment from James Lee to Tom Varvaro, sent July 6, 2016		

Trial Exhibit List - Dated 9/11/2019

Exhibit No.	Date	Description	Date Identified	Date Admitted
1289		Email and attachments from James Lee to Mark Morris, copying Troy Rhonemus, sent April 28, 2015 (Elysium Health Niagen Royalty Report, Q3 2014)		
1290		Email and attachment from Dan Alminana to James Lee and Tom Varvaro, copying Frank Jaksch, Mark Morris, Eric Marcotulli, sent June 17, 2015 (Elysium Health Niagen Royalty Report Q1 2015)		
1291		Email and attachment from Dan Alminana to James Lee, Tom Varvaro, copying Frank Jaksch, Mark Morris and Eric Marcotulli, sent December 17, 2015 (Elysium Health Niagen Royalty Report Q3 2015)		
1292		Email and attachment from Dan Alminana to James Lee, Tom Varvaro, copying Frank Jaksch, Troy Rhonemus, and Mark Morris, sent March 23, 2016 (Elysium Health Niagen Royalty Report Q4 2015)		
1293		Email and attachment from James Lee to Dan Alminana, Frank Jaksch, Tom Varvaro, Troy Rhonemus and Mark Morris, copying Eric Alminana (Elysium Health Niagen Royalty Report Q2 2016)		
1294		Document titled Supply Agreement Proposal (MAAC10)		
1295		Document titled Supply Agreement Proposal (MAAC10)		
1296		Letter from Will Black to Headley Lee, dated September 12, 2016		
1297		Email and attachment from ChromaDex Customer Service to hle@maac10.com, copying John Mai and Celine Norman, sent December 7, 2016		
1298		Email and attachment from Charles Brenner to Rob Fried, sent January 18, 2016		
1299		Email and attachments from Frank Jaksch to Giles Parisot, sent February 12, 2014		
1300		Email and attachment from Frank Jaksch to shenry@roth.com, copying Andrew Johnson, sent May 7, 2015		
1301		Excel file titled NIAGEN Resellers		
1302		Letter from Heather Van Blarcom to Daureen Papinchak, dated November 13, 2017 (Termination of Nordic Clinical Supply Agreement)		
1303		Letter from Heather Van Blarcom to Brian Nettles, dated April 26, 2017(Termination of Alivebynature Niagen Supply Agreement)		
1304		Email and attachment from Will Black to Kartik Chandrasekara		
1305		Document titled Where to Buy Niagen		
1306		Email from Reto Rieder to John Mai, sent December 8, 2016		

Exhibit No.	Date	Description	Date Identified	Date Admitted
1307		Email from Dan Alminana to Will Black, copying Eric Marcotulli, Troy Rhonemus, Frank Jaksch, and Tom Varvaro, sent August 20, 2016		
1308		Compilation of quotes and invoices from Gibraltar Laboratories dated from September 2017 to December 2017		
1309		Compilation of invoices from Elysium's NR contract manufacturer dated from January 2017 to December 2017		
1310		Email from Bob Prag to Frank Jaksch, sent October 10, 2013		
1311		Email and attachment from Frank Jaksch to Eric Marcotulli, copying Dan Alminana, Robert Prag and Leonard Pershing Guarente, sent December 20, 2013		
1312		Email from Mark Morris to Ramon Padilla, sent August 3, 2017		
1313		ChromaDex's Amended Notice of Deposition Pursuant to Fed. R. Civ. P. 30(b)(6)		
1314		Certified copy of U.S. Patent No. 8,106,184 - Nicotinoyl Riboside Compositions and Methods of Use		
1315		Certified copy of U.S. Patent No. 8,114,626 - Yeast Strain and Method for Using the Same to Produce Nicotinamide Riboside		
1316		Certified copy of U.S. Patent No. 8,197,807 - Nicotinamide Riboside Kinase Compositions and Methods for Using the Same		
1317		Certified copy of U.S. Patent No. 8,383,086 - Nicotinamide Riboside Kinase Compositions and Methods for Using the Same		
1318		Certified copy of U.S. Patent No. 7,776,326 - Methods and Compositions for Treating Neuropathies		
1319		Certified copy of U.S. Patent No. 9,000,147 - Nicotyl Riboside Compositions and Methods of Use		
1320		Certified copy of U.S. Patent No. 9,321,797 - Nicotinoyl Riboside Compositions and Methods of Use		
1321		Certified copy of U.S. Patent No. 8,889,126 - Methods and Compositions for Treating Neuropathies		
1322		Certified copy of U.S. Patent No. 9,295,688 - Methods and Compositions for Treating Neuropathies		

Trial Exhibit List - Dated 9/11/2019

Exhibit No.	Date	Description	Date Identified	Date Admitted
1323		Certified copy of U.S. Patent No. 9,975,915 - Crystalline Forms of Nicotinoyl Ribosides, Modified Derivatives Thereof, and Phosphorylated Analogs Thereof, and Methods of Preparation Thereof		
1324		Certified copy of U.S. Patent No. 10,000,520 - B-Vitamin and Amino Acid Conjugates of Nicotinoyl Ribosides and Reduced Nicotinoyl Ribosides, Derivatives Thereof, and Methods of Preparation Thereof		
1325		email from Elysium's NR contract manufacturer to Mark Morris, attaching acetamide testing chromatographs		
1326		PTAB IPR decision on Dartmouth patent (PTAB Docket: IPR2017-01795) (CERTIFIED), January 16, 2019		
1327		Dartmouth Motion to Withdraw Appeal (Federal Circuit Docket No. 19-1630) Cases to be terminated: 19-1682 (Doc No. 17) (CERTIFIED) August 14, 2019		
1328		CAFC Order Granting Dartmouth Motion to Withdraw Appeals (Federal Circuit Docket No. 19-1630) (Doc. No. 18) (CERTIFIED) August 19, 2019		
1329		October 9, 2013 Email chain between Eric Marcotulli, Frank Jaksch, Dan Alminana, Leonard Guarente, Bob Prag RE: Follow-Up: Summary Terms with attachment EH/CDXC Partnership Proposal		
1330		October 8, 2013 Email chain between Frank Jaksch, Dan Alminana, Eric Marcotulli, Leonard Guarente, Bob Prag RE: Follow-up: Summary Terms with attachment ChromaDex Elysium Niagen Draft Term Sheet		
1331		ChromaDex Form 8-K		
1332		Is NR really just an anti-aging supplement? Tru NIAGEN Blog		
1333		What's so special about NR? Tru NIAGEN Blog		
1334		8 Key differences between NR and NMN - Tru NIAGEN Blog		
1335		More Scientific Data - Tru NIAGEN Blog		
1336		ChromaDex Form 10-K (CERTIFIED) 2018		
1337		ChromaDex Form 10-K 2018		
1338		ChromaDex Form 10-K (CERTIFIED) 2017		
1339		ChromaDex Form 10-K 2017		
1340		ChromaDex Form 10-Q (CERTIFIED) 3/31/2018		
1341		ChromaDex Form 10-Q 3/31/2018		

Exhibit No.	Date	Description	Date Identified	Date Admitted
1342		ChromaDex Form 10-Q 3/31/2018		
1343		ChromaDex Form 8-K (CERTIFIED) 12/4/2018		
1344		ChromaDex Form 8-K (CERTIFIED) 7/9/2013		
1345		ChromaDex Form 8-K (CERTIFIED) 6/2/2014		
1346		ChromaDex Form 10-Q (CERTIFIED) 10/3/2015		
1347		ChromaDex Form 10-Q (CERTIFIED) 4/1/2017		
1348		ChromaDex Form 10-Q 4/1/2017		
1349		ChromaDex Form 10-K (CERTIFIED) 1/3/2015		
1350		ChromaDex Form 10-K (CERTIFIED) 1/1/2011		
1351		Certified copy of July 9 2013 8-K (CERTIFIED) 7/9/3013		
1352		Certified copy of March 2018 10-Q		
1353		Niagen Branding Bottle Photographs		
1354		Do NAD Supplements Work? Tru NIAGEN Blog		
1355		Elysium Website - What is Nicotinamide Riboside		
1356		ChromaDex and Nestle Health Science Enter Global Commercial License and Supply Agreement for TRU NAGEN Press Release 12/20/2018		
1357		ChromaDex website Tru NIAGEN, Age Better Live Better		
1358		ChromaDex: Response To The Claim NIAGEN Is Just "Expensive Vitamin B3" Seeking Alpha Article		
1359		ChromaDex Form 10-K		
1360		ClinicalTrials.gov Search Results		
1361		November 28 2016 Email from Frank Jaksch to K. Farr RE: Pharma Deck from BIO Last Month with attachment ChromaDex Connection Investor Presentation BIO Investor Forum October 2017		
1362		NIAGEN Supply Agreement between ChromaDex and 5Linx Enterprises, Inc.		
1363		NIAGEN Supply Agreement between ChromaDex and Healthy Directions LLC		
1364		ChromaDex Connection Investor Presentation		
1365		ChromaDex Connection Investor Presentation		
1366		ChromaDex Connection Investor Presentation		
1367		Limited Liability Agreement of HealthSpan Research, LLC (Not Executed)		

Exhibit No.	Date	Description	Date Identified	Date Admitted
1368		ChromaDex Form 10-Q		
1369		November 24, 2015 Email from Andrew Johnson to James Lee Cc: Tom Varvaro RE: ChromaDex to Present at 27th Annual Piper Jaffray Healthcare Conference with attachment ChromaDex Connection Investor Presentation December 2015		
1370		NIAGEN Supply Agreement between ChromaDex and Elysium Health, LLC		
1371		Amendment to Supply Agreement between ChromaDex and Elysium Health, LLC		
1372		August 8, 2016 Email chain between Tom Varvaro, S. Van Winkle, Andrew Johnson, Frank Jaksch, Breah Ostendorf RE: Follow-Up with attachment ChromaDex Connection Investor Presentation May 2016		
1373		September 11, 2013 Email from Eric Marcotulli to Frank Jaksch, Cc: Dan Alminana RE: Follow-up: Summary Terms		
1374		June 14, 2014 Email from B. Rotter to Frank Jaksch RE: Fwd: ChromaDex: Look at This!! with attachment ChromaDex Investor Presentation May 2013		
1375		Manufacturing and Supply Agreement Between ChromaDex and W.R. Grace & Co.-Conn		
1376		Supply Agreement between ChromaDex and High Performance Nutrition LLC		
1377		ChromaDex Form 10-K (1/3/2015)		
1378		ChromaDex Project Crimson Presentation		
1379		February 19, 2016 Email from Greg Horn to Frank Jaksch RE: FW: NAD Precursor / ChromaDex Advance Deck with attachment NR as a Therapeutic Platform Presentation February 2016		
1380		May 1, 2017 Email from Frank Jaksch to W. Yu, Cc: J. Ho, P. Zhang, Robert Fried, T. Lau RE: Congratulations to Rob and your VR Team with attachment NIAGEN Presentation May 1, 2017		
1381		ChromaDex, Inc. - Dartmouth Exclusive License Agreement		
1382		Supply Agreement between ChromaDex and Elysium Health, LLC		
1383		October 14, 2016 Email chain between John Mai and H. Lehmann RE: Nicotinamide Riboside		
1384		Exclusive License Agreement between ChromaDex and Washington University		

Trial Exhibit List - Dated 9/11/2019

Exhibit No.	Date	Description	Date Identified	Date Admitted
1385		August 8 , 2017 Email from Frank Jaksch to T. Lau RE: FW: Agenda with attachments Minutes of a Telephonic Meeting of The Board of Directors of ChromaDex Corporation July 17, 2017; August 8th, 7th, 207 BOD Meeting, Amazon Tracker for NR Products, i.e. NIAGEN Resellers with Inventory		
1386		December 1, 2017 Email from K. Farr to Frank Jaksch, Cc: Andrew Johnson RE: CDXC Investor Presentation with attachment ChromaDex Investor Presentation, Investor Meeting December 2017		
1387		March 3, 3017 Email from Tom Varvaro to M. Tillotson Cc: Z. Nigent, K. Sabin RE: Valuation with attachments Delaware Certificate of Formation of HealthSpan Research LLC; ChromaDex Meeting February 10, 2017 Presentation; Letter from Scalar to Tom Varvaro re: Engagement for Valuation Services, March 3, 2017; HealthSpan Balance Sheet		
1388		NIAGEN Ingredients Fact Sheet		
1389		July 25, 2014 Email chain between Siva Hari, Frank Jaksch, Mark Morris, Stephen Olmstead, S. Rheault, and E. Hauck RE: NIAGEN		
1390		August 31, 3017 Email chain between Frank Jaksch and S. Moffett RE: My NR questions		
1391		October 18, 2017 Email from Frank Jaksch to Andrew Johnson RE: Boi Presentation with attachment ChromaDex Connection Investor Presentation Bio Investor Forum, October 2017		
1392		September 22, 2015 Letter from GRACE to ChromaDex RE: Take or Pay Purchase Agreement for Nicotinamide Riboside Chloride		
1393		ChromaDex Form 8-K		
1394		Cornerstones for Potential Agreement with HealthSpan		
1395		Grace Davison Invoice, PO05610		
1396		Grace Davison Invoice, PO5460		
1397		Grace Davison Invoice, PO06049		
1398		Grace Davison Invoice, PO05973		
1399		Grace Davison Invoice, PO05611		
1400		November 13, 2017 Notice of Termination of NIAGEN Supplement Agreement between ChromaDex and High Performance Nutrition, LLC		

Exhibit No.	Date	Description	Date Identified	Date Admitted
1401		June 27, 2016 Email chain between Andrew Johnson, Frank Jaksch, Tom Varvaro, Breah Ostendorf, Will Black RE: Final Look Before Article Submission with attachment Interview with ChromaDex CEO Frank Jaksch		
1402		Niagen Supply Agreement (Thorne)		
1403		Niagen Specifications		
1404		pTeroPure Specifications		
1405		Email from Ryan Dellinger to Claire Kruger, Dietrich Conze, Juan Crespo-Barreto, copying Troy Rhonemus, sent August 7, 2015		
1406		Manufacturing and Supply Agreement Between ChromaDex and W.R. Grace & Co.-Conn		
1407		Email from Troy Rhonemus to Brett Reynolds, sent February 8, 2016		
1408		Email from Troy Rhonemus to Brett Reynolds, copying Audrey Kelleman, sent March 9, 2016		
1409		Email from Troy Rhonemus to Brett Reynolds sent May 10, 2016		
1410		ChromaDex Analytical Method		
1411		Investigator's Brochure for Niagen		
1412		Expert Panel Report for The Generally Recognized as Safe (GRAS) Status of pTeroPure		
1413		pTeroPure Supply Agreement between ChromaDex and Elysium Health		
1414		Presentation		
1415		Niagen Study Data		
1416		Letter from Dan Alminana to Mark Morris, copying Eric Marcotulli, sent July 15, 2016		
1417		Mark Morris Resume Presentation		
1418		Email from Mark Morris to Dan Alminana and Eric Marcotulli, sent June 23, 2016		
1419		Tru Niagen Website - Is Your Nicotinamide Riboside Authentic, Safe, & Effective?		
1420		Article "ChromaDex agrees to purchase division of HPN responsible for Niagen"		
1421		Tru Niagen Website - Is Your Nicotinamide Riboside Authentic, Safe, & Effective?		
1422		Horizontal Merger Guidelines from U.S. Department of Justice and the Federal Trade Commission		
1423		OECD Policy Roundtables, Market Definition, 2012		

Exhibit No.	Date	Description	Date Identified	Date Admitted
1424		ChromaDex 10-K for fiscal year ended December 31, 2016		
1425		ChromaDex Press Release "ChromaDex to Present at the 39th Annual Cowen Health Care Conference"		
1426		About Us - Specialty Nutrition Webpage		
1427		Basis NAD+ Supplement Webpage		
1428		https://www.chromadex.com/patents		
1429		https://biology.mit.edu/profile/leonard-p-guarente/		
1430		https://www.elysiumhealth.com/en-us/basis		
1431		https://www.elysiumhealth.com/en-us/plans-pricing		
1432		ChromaDex Form 10-K (2016)		
1433		ChromaDex Form 10-K (2017)		
1434		http://investors.chromadex.com/phoenix.zhtml?c=212121&p=irol-newsArticle&ID=2384497 .		
1435		http://phx.corporate-ir.net/External.File?item=UGFyZW50SUQ9MzQ1NjIwfnENoaWxkSUQ9LTF8VHlwZT0z&t=1&cb=636051688984896349		
1436		https://www.docdroid.net/AJLBuaW/cdxa-atr-8292-00-ord79140-nicotinamide-riboside-chloride.pdf ;		
1437		https://www.fda.gov/files/food/published/GRAS-Notice-000635--Nicotinamide-riboside-chloride.pdf ;		
1438		http://d18rn0p25nwr6d.cloudfront.net/CIK-0001386570/bb257127-d60c-433d-9a5a-712898864580.pdf .		
1439		https://www.lifeextension.com/magazine/2014/11/the-youth-restoring-benefits-of-nad/page-01?p=1 .		
1440		https://www.chromadex.com/leadership/		
1441		https://specialtynutrition.com/about-us		
1442		Email and attachemnt from Ryan Dellinger to Troy Rhonemus and Mark Morris, copying Syleesh Venkataraman, sent May 11, 2015.		
1443		Email and attachment from Ryan Dellinger to Frank Jaksch and Troy Rhonemus, sent May 11, 2015		
1444		Email and attachment from Troy Rhonemus to Frank Jaksch, sent May 11, 2015.		

Trial Exhibit List - Dated 9/11/2019

Exhibit No.	Date	Description	Date Identified	Date Admitted
1445		Email and attachment from Ryan Dellinger to Troy Rhonemus and Frank Jaksch, copying Mark Morris, sent May 12, 2015		
1446		Email from Mark Morris to Erica K. Bullard, sent January 16, 2014.		
1447		Email from Mark Morris to Adina Mayerhoff, sent June 27, 2013.		
1448		Email from Mark Morris to Adina Mayerhoff, sent June 27, 2013.		
1449		Email from Mark Morris to Clay Dubose, sent November 21, 2014.		
1450		Email from Mark Clemens to Mark Morris, copying Josh Golder and Zaid Mendez, sent November 24, 2014.		
1451		Email from Mark Morris to Arjun Avila, sent July 9, 2015.		
1452		Email from Mark Morris to Dan Southwick, sent August 22, 2015.		
1453		Email and attachments from Mark Morris to Matt Trip, sent September 20, 2013.		
1454		Email and attachment from Mark Morris to maxrx@aol.com, sent June 11, 2013.		
1455		Email and attachments from Mark Morris to Nicole Trelous, sent June 24, 2013.		
1456		Email and attachments from Mark Morris to Kathi Head and Alan Miller, copying Ann Deren Lewis, sent August 8, 2013.		
1457		Email and attachment from Mark Morris to Adina Mayerhoff, sent May 21, 2014.		
1458		Email and attachment from Mark Morris to Debbie Grossblat, copying Aaron Biesbrock, Tomohiro Hakozaki, John Oblong, Jesus Velazquez, Carl Margraf, Heather Rocchetta, James Dunbar, John French, and Troy Rhoenmus, sent April 24, 2015.		
1459		Email and attachment from Mark Morris to Debbie Grossblat, copying Aaron Biesbrock, Tomohiro Hakozaki, John Oblong, Jesus Velazquez, Carl Margraf, Heather Rocchetta, James Dunbar, John French, and Troy Rhoenmus, sent April 29, 2015.		
1460		Email and attachments from Mark Morris to Shawn Wells, sent August 29, 2013		
1461		Email from Mark Morris to Mark Clemens, Josh Golder, Dominic Galvin and Arjun Avila, copying Troy Rhonemus, sent February 7, 2015.		
1462		Email from Mark Morris to Shawn Wells, sent January 29, 2015.		
1463		Email from Mark Morris to Arjun Avila, sent February 7, 2015.		
1464		Email from Mark Morris to Josh Golder, sent August 12, 2014.		

Exhibit No.	Date	Description	Date Identified	Date Admitted
1465		Email from Mark Morris to le-brandon@robinsonpharma.com, copying Mina Kami, sent August 1, 2015.		
1466		Email and attachments from James Lee to Nila D. Bhakuni, copying Tom Varvaro and Patrick Bradley, sent September 7, 2017.		
1467		Email and attachment from James Lee to Tom Varvaro, sent February 2, 2017.		
1468		https://www.amazon.com/thrive-now-health-nicotinamide-ribose/dp/B01EL0MXFY		
1469		https://www.amazon.com/nicotinamide-ribose-vegetarian-capsules-activator/dp/B01CUNRXWW		
1470		https://www.amazon.com/live-cell-research-niagen-nicotinamide/dp/B00PZ7E3J2		
1471		https://niagenexperience.com/reorder		
1472		https://supplementpolice.com/maac-10-niagen-trans-resveratrol/		
1473		Email and attachments from John Mai to Agnieszka Laskosz, sent January 9, 2018		
1474		Email from Troy Rhonemus to Tom Varvaro, sent February 6, 2016.		
1475		Email and attachment from James Lee to Tom Varvaro, sent January 27, 2017		
1476		Email and attachment from Tom Varvaro to James Lee, sent November 4, 2016		
1477		https://www.keystonebioanalytical.com/services/list-of-validated-assays/		
1478		Niagen Supply Agreement between ChromaDex and Nectar 7, dated August 28, 2015.		
1479		Niagen Supply Agreement between ChromaDex and Previta, dated October 12, 2016		
1480		Trademark and License Agreement between ChromaDex and Alivebynature, dated November 18, 2016		
1481		Trademark and License Agreement between ChromaDex and Barology Bar LLC, dated March 16, 2016.		
1482		Trademark and License Agreement between ChromaDex and Jarrow Formulas, dated January 12, 2015.		
1483		Trademark and License Agreement between ChromaDex and Nexgen Pharma, dated December 29, 2014.		
1484		Trademark and License Agreement between ChromaDex and MAAC10		
1485		Trademark and License Agreement between ChromaDex and MAAC10		
1486		Trademark and License Agreement between ChromaDex and MAAC10		

Trial Exhibit List - Dated 9/11/2019

Exhibit No.	Date	Description	Date Identified	Date Admitted
1487		Signature Page of Trademark ad License Agreement between ChromaDex and Whole Body Research		
1488		Niagen Supply Agreement between ChromaDex and Exclusion Nutrition, dated August 15, 2016		
1489		Niagen Supply Agreement between ChromaDex and Life in Balance, dated October 12, 2016.		
1490		Niagen Supply Agreement between ChromaDex and VitaMonk, dated October 12, 2016.		
1491		Niagen Supply Agreement between ChromaDex and Living Cell		
1492		Niagen Supply Agreement between ChromaDex and Radishign Medical, dated January 10, 2017.		
1493		Email and attachments from David D'Arcangelo to Frank Jaksch and cdrapeau@stemtechmail.com, sent September 12, 2013.		
1494		Email from Charles Brenner to Rob Fried and Frank Jaksch, sent January 10, 2017.		